

# World Journal of *Stomatology*

*World J Stomatol* 2013 February 20; 2(1): 1-29



## Editorial Board

2011-2015

The *World Journal of Stomatology* Editorial Board consists of 345 members, representing a team of worldwide experts in stomatology. They are from 48 countries, including Australia (5), Austria (2), Belgium (3), Brazil (24), Bulgaria (1), Canada (4), Chile (1), China (24), Colombia (1), Croatia (1), Denmark (2), Egypt (6), Finland (3), France (4), Germany (7), Greece (8), Hungary (1), India (28), Iran (5), Israel (12), Italy (28), Japan (18), Jordan (7), Malaysia (5), Mexico (4), Myanmar (1), Netherlands (1), New Zealand (2), Nigeria (6), Norway (1), Poland (1), Portugal (3), Saudi Arabia (4), Serbia (1), Singapore (1), South Africa (1), South Korea (4), Spain (3), Sri Lanka (2), Sudan (1), Sweden (8), Switzerland (4), Tanzania (1), Thailand (8), Turkey (29), United Arab Emirates (2), United Kingdom (7), and United States (50).

### EDITOR-IN-CHIEF

Peter E Murray, *Fort Lauderdale*

### GUEST EDITORIAL BOARD MEMBERS

Da-Tian Bau, *Taichung*  
Kuo-Wei Chang, *Taipei*  
Mu-Kuan Chen, *Changhua*  
Shih-Shun Chen, *Taichung*  
Shu-Ching Chen, *Taoyuan*  
Wei-Fan Chiang, *Tainan*  
Jiiang-Huei Jeng, *Taipei*  
Sang-Heng Kok, *Taipei*  
Iebin Lian, *Changhua*  
Chun-Pin Lin, *Taipei*  
Chi-Cheng Tsai, *Taichung*

### MEMBERS OF THE EDITORIAL BOARD



#### Australia

Jaafar Abduo, *Crawley*  
Anut Itthagaran, *Southport*  
Arash Nikgoo, *Prospect*  
Sarbin Ranjitkar, *Adelaide*  
Qingsong Adam Ye, *Cairns*



#### Austria

Kurt Alexander Schicho, *Vienna*  
Gerlig Widmann, *Innsbruck*



#### Belgium

Jimoh Olubawo Agbaje, *Leuven*  
Hugo De Bruyn, *Ghent*

Sven Saussez, *Mons*



#### Brazil

Miguel G Setubal Andrade, *Cabula*  
M de Oliveira Barceiro, *Nova Friburgo*  
Ricardo Carneiro Borra, *Sao Paulo*  
Bernardo Brasileiro, *Aracaju*  
Fernanda Brito, *Rio de Janeiro*  
Maximiliano S Cenci, *Pelotas*  
Fabio Andre dos Santos, *Ponta Grossa*  
Anderson J Ferreira, *Belo Horizonte*  
CM da Silva Figueredo, *Rio de Janeiro*  
Mariana Fampa Fogacci, *Rio de Janeiro*  
Ana Lúcia Franco, *Araraquara*  
Daniela AG Gonçalves, *Araraquara*  
Personal History, *Taubate*  
Marinella Holzhausen, *São Paulo*  
Martinho C Rebello Horta, *Minas Gerais*  
Caio Cesar de Souza Loureiro, *São Paulo*  
Beatriz Silva Câmara Mattos, *São Paulo*  
Michel R Messoro, *Ribeirão Preto*  
Arthur Belem Novaes Jr, *Ribeirao Preto*  
Lucinei Roberto Oliveira, *Minas Gerais*  
Ana Carolina Prado Ribeiro, *Piracicaba*  
Adalberto Luiz Rosa, *Ribeirao Preto*  
Paulo Sergio da Silva Santos, *Bauru*  
FW Garcia de Paula e Silva, *Ribeirao Preto*



#### Bulgaria

Angel Georgiev Bakardjiev, *Sofia*



#### Canada

Reginaldo Bruno Gonçalves, *Québec*  
Daniel Grenier, *Laval*

Anuradha Prakki, *Toronto*  
Mahmoud Rouabhia, *Québec*



#### Chile

Emma Marcela Hernandez Rios, *Santiago*



#### China

Wei-Liang Chen, *Guangzhou*  
Shiu-Yin Cho, *Hong Kong*  
Deng-Hui Duan, *Beijing*  
Tao Hu, *Chengdu*  
Gang Li, *Beijing*  
Ming-Yu Li, *Shanghai*  
He-Ming Lu, *Nanning*  
Sheng-Hua Wei, *Harbin*  
Ricky Wing Kit Wong, *Hong Kong*  
Hao Yu, *Fuzhou*  
Rong-Sheng Zeng, *Guangzhou*  
Jia-Wei Zheng, *Shanghai*  
Lai-Ping Zhong, *Shanghai*



#### Colombia

Carlos Martin Ardila, *Medellín*



#### Croatia

Kristina Gorseta, *Zagreb*



#### Denmark

Rodrigo López, *Aarhus*  
Frances M Andreasen, *Copenhagen*



### Egypt

Mohamed Farag Ayad, *Tanta*  
 Ahmed Samir Bakry, *Alexandria*  
 Farid S El-Askary, *Cairo*  
 Ahmed Abdel Rahman Hashem, *Cairo*  
 Mostafa Ibrahim Mostafa, *Cairo*  
 Weam Ahmad Maher Rashwan, *Cairo*



### Finland

Hadi Ghasemi, *Helsinki*  
 Yrjö Tapio Konttinen, *Biomedicum*  
 Arzu Tezvergil-Mutluay, *Turku*



### France

Laurent Dupoirieux, *Paris*  
 Michel Goldberg, *Paris*  
 Francis Mora, *Paris*  
 Jacques-Olivier Pers, *Brest Cedex*



### Germany

Bilal Al-Nawas, *Mainz*  
 Christel Herold-Mende, *Heidelberg*  
 Anahita Jablonski-Momeni, *Marburg*  
 Adrian Kasaj, *Mainz*  
 Christian Morszeck, *Regensburg*  
 Urs Müller-Richter, *Würzburg*  
 Afshin Teymoortash, *Marburg*



### Greece

Kyrgidis Athanassios, *Thessaloniki*  
 Koliniotou-K Eugenia, *Thessaloniki*  
 Petros Koidis, *Thessaloniki*  
 Sotirios Kotsovilis, *Athens*  
 Konstantinos X Michalakakis, *Thessaloniki*  
 Moschos A Papadopoulos, *Thessaloniki*  
 Christos N Yapijakis, *Athens*  
 Spiros Zinelis, *Athens*



### Hungary

Zsuzsanna Suba, *Üllői út*



### India

Ashish Aggarwal, *Bareilly*  
 Vivek Aggarwal, *New Delhi*  
 Punnya V Angadi, *Belgaum*  
 Deepika Bablani, *New Delhi*  
 N Vasudev Ballal, *Manipal*  
 Saurab Bither, *Sirhind*  
 Revant H Chole, *Bhopal*  
 Ramesh Chowdhary, *Bangalore*  
 Satya N Das, *New Delhi*  
 Gingu Koshy George, *Kerala*  
 Rajshekhar Halli, *Pune*  
 Jojo Kottoor, *Kochi*  
 Thilla Sekar Vinoth Kumar, *Chennai*  
 Ajay Mahajan, *Shimla*

Ravi Mehrotra, *Allahabad*  
 Prasanna Neelakantan, *Tamil Nadu*  
 Anand Chidanand Patil, *Belgaum*  
 Pravinkumar G Patil, *Nagpur*  
 Vidya Rattan, *Chandigarh*  
 Gaurav Sharma, *New Delhi*  
 Saumyendra Vikram Singh, *Lucknow*  
 Gokul Sridharan, *Navimumbai*  
 Shobha Tandon, *Karnataka*  
 Nitesh Tewari, *Lucknow*  
 Manuel Sebastian Thomas, *Mangalore*  
 Shaji Thomas, *Bhopal*  
 Milind M Vaidya, *Navi Mumbai*  
 Prapulla Venkataramaiah, *Bangalore*



### Iran

Marzieh Alikhasi, *Tehran*  
 Hamid Jafarzadeh, *Mashhad*  
 Mohammad H Kalantar Motamedi, *Tehran*  
 Donia Sadri, *Tehran*  
 Shahriar Shahi, *Tabriz*



### Israel

Dror Aizenbud, *Haifa*  
 Imad Abu El-Naaj, *Nofit*  
 Iris Slutzky Goldberg, *Jerusalem*  
 Yoav Leiser, *Haifa*  
 Liran Levin, *Haifa*  
 Saul Lin, *Haifa*  
 Joseph Nissan, *Tel-Aviv*  
 Micha Peled, *Haifa*  
 Devorah Schwartz-Arad, *Ramat Hasharon*  
 Haim Tal, *Tel Aviv*  
 Yehuda Zadik, *Jerusalem*  
 Uri Lucian Zilberman, *Ashkelon*



### Italy

Roberto Abundo, *Torino*  
 Fabio D Amico, *Catania*  
 Scribante Andrea, *Pavia*  
 Claudio Arcuri, *Rome*  
 Giovanni N Berta, *Torino*  
 Paolo Boffano, *Turin*  
 Paolo Boscolo-Rizzo, *Treviso*  
 Gaetano Calesini, *Rome*  
 Giuseppina Campisi, *Palermo*  
 Guglielmo Giuseppe Campus, *Sassari*  
 Francesco Carinci, *Ferrara*  
 Enrico Conserva, *Albenga*  
 Claudia Dellavia, *Milan*  
 Alfio Ferlito, *Udine*  
 Andrea Ferri, *Parma*  
 Pierfrancesco Rossi Iommetti, *Rome*  
 Giuseppe Isgro, *Barcellona*  
 Giovanni Lorenzo Lodi, *Milano*  
 Lorenzo Lo Muzio, *Foggia*  
 Giuseppina Nocca, *Rome*  
 Giovanna Orsini, *Ancona*  
 Gianluca Plotino, *Rome*  
 Luigi Fabrizio Rodella, *Brescia*  
 Gianrico Spagnuolo, *Napoli*  
 Giorgio Tabanella, *Rome*  
 Simona Tecco, *Pescara*  
 Corrado Toro, *Ragusa*  
 Mario Veltri, *Siena*



### Japan

Junichi Asaumi, *Okayama city*  
 Miyuki Azuma, *Tokyo*  
 Kazuyoshi Baba, *Tokyo*  
 Yoshitaka Fujii, *Tokyo*  
 Saburo Hidaka, *Fukuoka*  
 Masaki Honda, *Tokyo*  
 Masato Hotta, *Mizuho-city*  
 Atsushi Kameyama, *Chiba*  
 Hiroyuki Kanzaki, *Miyagi-pref*  
 Takeshi Kikuchi, *Aichi*  
 Katsuaki Mishima, *Ube*  
 Takuro Sanuki, *Osaka*  
 Hidenobu Senpuku, *Tokyo*  
 Hidetoshi Shimauchi, *Sendai*  
 Hiroshi Sugiya, *Fujisawa*  
 Tomoki Sumida, *Ehime*  
 Takaaki Tomofuji, *Okayama*  
 Akihiro Yoshida, *Kitakyushu*



### Jordan

Taiseer H Al-Khateeb, *Irbid*  
 Fidaa Almomani, *Irbid*  
 Lama Awawdeh, *Irbid*  
 Najla Dar-Odeh, *Amman*  
 Ahmad A Salam Ahmad Hamdan, *Amman*  
 Mohammad Hammad, *Amman*  
 Ma'amon A Rawashdeh, *Irbid*



### Malaysia

Shani Ann Mani, *Kuala Lumpur*  
 Wei Cheong Ngeow, *Kuala Lumpur*  
 Abhishek Parolia, *Kuala Lumpur*  
 Wihaskoro Sosroseno, *Kedah Darul Aman*  
 Maen Zreaqat, *Kota Bharu*



### Mexico

Ronell Bologna-Molina, *Durango*  
 Carlo Eduardo Medina Solis, *Hidalgo*  
 Jorge Paredes Vieyra, *Tijuana*  
 Rogelio José Scougall Vilchis, *Toluca*



### Myanmar

Myat Nyan, *Yangon*



### Netherlands

Yijin Ren, *Groningen*



### New Zealand

Alan Graham Thomas Payne, *Whangarei*  
 Donald Royden Schwass, *Dunedin*



### Nigeria

Wasiu Lanre Adeyemo, *Lagos*  
 Adekoya S Comfort Ayodele, *Osun State*

Chima Oji, *Enugu*  
Hector Oladapo Olosoji, *Maiduguri*  
Christopher Ikeokwu Udoye, *Enugu*  
Vincent Ifechukwukwu Ugboko, *Ile-Ife*



#### Norway

Vaska Vandevska-Radunovic, *Oslo*



#### Poland

Katarzyna Emerich, *Gdansk*



#### Portugal

Eunice Palmeirão Carrilho, *Coimbra*  
Manuel Marques Ferreira, *Coimbra*  
Rui Amaral Mendes, *Porto*



#### Saudi Arabia

Solaiman M Al-Hadlaq, *Riyadh*  
Mohammad S Al-Zahrani, *Jeddah*  
Anil Sukumaran, *Riyadh*  
Santhosh Kumar Tadakamadla, *Jazan*



#### Serbia

Ivana Radovic, *Beograd*



#### Singapore

Goh Bee Tin, *Singapore*



#### South Africa

Johannes Petrus Reyneke, *Morningside*



#### South Korea

Dong Kuk Ahn, *Daegu*  
Sung-Dae Cho, *Jeonju*  
Jong-Ho Lee, *Seoul*  
Hyo-Sang Park, *Daegu*



#### Spain

Guillermo Quindos Andres, *Bilbao*  
Pía López-Jornet, *Murcia*  
Miguel A Iglesia Puig, *Zaragoza*



#### Sri Lanka

Thiraviam Sabesan, *Badulla*  
WM Tilakaratne, *Peradeniya*



#### Sudan

Neamat Hassan Abu-bakr, *Khartoum*



#### Sweden

Majid Ebrahimi, *Umeå*  
Jorgen Ekstrom, *Gothenburg*  
Lars Eliasson, *Strömstad*  
Karl-Erik Kahnberg, *Gothenburg*  
Tomas Magnusson, *Jonkoping*  
Kerstin Elisabeth Schander, *Gothenburg*  
Young-Taeg Sul, *Gothenburg*  
Inger Margareta Wårdh, *Huddinge*



#### Switzerland

Marco Aglietta, *Bern*  
Heinz-Theo Lübbers, *Zurich*  
Mutlu Özcan, *Zurich*  
Tobias T Tauböck, *Zurich*



#### Tanzania

Febronia K Kahabuka, *Dar es salaam*



#### Thailand

Orapin Ajcharanukul, *Bangkok*  
Kittipong Dhanuthai, *Chulalongkorn*  
Boonlert Kukiattrakoon, *Songkhla*  
Rangsini Mahanonda, *Bangkok*  
Wipawee Nittayananta, *Songkhla*  
Prisana Pripatnanont, *Songkhla*  
Suwimol Taweetchaisupapong, *Khon Kaen*  
Viroj Wiwaintkit, *Bangkok*



#### Turkey

Hasan Ayberk Altug, *Ankara*  
Hatice Altundal, *Istanbul*  
Taner Arabaci, *Erzurum*  
Volkan Arisan, *Istanbul*  
Funda Bayindir, *Erzurum*  
Mehmet Emre Benlidayi, *Adana*  
Giray Bolayir, *Sivas*  
Isil Cekic-Nagas, *Ankara*  
Cetin Celenk, *Samsun*  
Ayhan Comert, *Ankara*  
Candan Efeoglu, *Izmir*  
Ugur Erdemir, *Istanbul*  
Onur Geckili, *Istanbul*  
Osman Gokay, *Ankara*  
Nurhan Guler, *Istanbul*  
Sema S Hakki, *Konya*  
Kivanc Kamburoglu, *Ankara*  
Burcak Kaya, *Ankara*  
Guvenc Kayaoglu, *Ankara*  
Yonca Korkmaz, *Ankara*  
Burcu Bal Kucuk, *Istanbul*  
Hüsametttin Oktay, *Istanbul*  
Zeynep Ökte, *Ankara*  
İrfan Özyazgan, *Kayseri*  
Ilkay Peker, *Ankara*  
Gürel Pekkan, *Kutahya*  
Tolga Fikret Tözüm, *Ankara*  
Aslihan Usumez, *Istanbul*  
Hasan Güney Yilmaz, *Mersin*



#### United Arab Emirates

Natheer Hashim Al-Rawi, *Sharjah*  
Vellore Kannan Gopinath, *Sharjah*



#### United Kingdom

Vyomesh Bhatt, *Birmingham*  
Leandro Chambrone, *Cochrane*  
Marcus Mau, *London*  
Muzzammil A Nusrath, *Newcastle*  
Salvatore Sauro, *London*  
Mohammad Owaise Sharif, *Manchester*  
Muy-Teck Teh, *London*



#### United States

Sercan Akyalcin, *Houston*  
Ben Balevi, *Vancouver*  
Indraneel Bhattacharyya, *Gainesville*  
Nabil F Bissada, *Cleveland*  
James L Borke, *Augusta*  
Gerard Byrne, *Lincoln*  
John H Campbell, *Buffalo*  
Jack Caton, *Rochester*  
Shuo Chen, *San Antonio*  
Diane Cummins, *Piscataway*  
Lawrence Gettleman, *Louisville*  
Violet Ibolya Haraszthy, *Buffalo*  
Richard Tsu-hsun Kao, *San Francisco*  
Joseph Katz, *Gainesville*  
Toshihisa Kawai, *Cambridge*  
Robert B Kerstein, *Medford*  
King Kim, *Rockledge*  
Tae Kim, *Los Angeles*  
Gary D Klasser, *Glenview*  
Jens Kreth, *Oklahoma*  
Ann W Kummer, *Cincinnati*  
Daniel M Laskin, *Richmond*  
Jaebum Lee, *Augusta*  
Renata Serricchio Leite, *Charleston*  
Louis M Lin, *New York*  
Zi-Jun Liu, *Seattle*  
Cheen Y Loo, *Brighton*  
William James Maloney, *New York*  
George A Mandelaris, *Park Ridge*  
Anwar T Merchant, *Columbia*  
Ivar Andreas Mjör, *Gainesville*  
Fatemeh Momen-Heravi, *Boston*  
Ana Nemeç, *Davis*  
Cornelis H Pameijer, *Simsbury*  
Pauline Chu Pan, *Morris Plains*  
Jae Hyun Park, *Mesa*  
Lilliam Marie Pinzón, *San Francisco*  
Charles Brian Preston, *East Amherst*  
Terry Dalton Rees, *Dallas*  
Fouad S Salama, *Omaha*  
Nachum Raphael Samet, *Boston*  
Joel Lawrence Schwartz, *Chicago*  
Othman Shibly, *Buffalo*  
G Dave Singh, *Beaverton*  
Alexandre Rezende Vieira, *Pittsburgh*  
Alessandro Villa, *Boston*  
Alvin G Wee, *Omaha*  
William Andrew Yeudall, *Richmond*  
Burak Yilmaz, *Columbus*



**FRONTIER** 1 Risk aspects of dental restoratives: From amalgam to tooth-colored materials  
*Frankenberger R, Garcia-Godoy F, Murray PE, Feilzer AJ, Krämer N*

**BRIEF ARTICLE** 12 Effects of low intensity laser irradiation phototherapy on dental pulp constructs  
*Elnaghy AM, Murray PE, Bradley P, Marchesan M, Namerow KN, Badr AE, El-Hawary YM, Badria FA*

18 Ozone action on *Streptococcus mutans* and *Lactobacillus fermentum*: A pilot study  
*Marques J, Paula A, Gonçalves T, Ferreira M, Carrilho E*

24 MMP-8 analysis in gingival crevicular fluid using ELISA and novel chair-side test  
*Akbari G, Prabhuji MLV, Karthikeyan BV, Chorghade SG*

**APPENDIX** I-V Instructions to authors

**ABOUT COVER** Editorial Board Member of *World Journal of Stomatology*, Michel R Messori, DDS, PhD, Department of Surgery and Bucco-Maxillofacial Traumatology and Periodontology, Ribeirao Preto School of Dentistry, University of Sao Paulo-USP, Av. Café s/n, 14040-904 Ribeirão Preto, SP, Brazil

**AIM AND SCOPE** *World Journal of Stomatology* (*World J Stomatol*, *WJS*, online ISSN 2218-6263, DOI: 10.5321) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

*WJS* covers topics concerning oral and craniofacial sciences, oral and craniofacial development/growth, dental tissue regeneration, craniofacial bone and cartilage research, oral and maxillofacial genetic diseases, developmental abnormalities and soft tissue defects, pulpal and periapical diseases, periodontal diseases and oral mucosal diseases, salivary gland diseases, oral and maxillofacial vascular/nervous diseases, jaw bone diseases, taste abnormalities, oral and maxillofacial pain, occlusion and temporomandibular diseases, repair and treatment of tooth defects, loss and dento-maxillofacial deformities, oral and maxillofacial biomechanics and biomaterials, new techniques for diagnosis/treatment of oral and maxillofacial diseases; and stomatology-related evidence-based medicine, epidemiology and nursing. Priority publication will be given to articles concerning diagnosis and treatment of stomatologic diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJS*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

**INDEXING/ABSTRACTING** *World Journal of Stomatology* is now indexed in Digital Object Identifier.

**FLYLEAF** I-III Editorial Board

**EDITORS FOR THIS ISSUE** Responsible Assistant Editor: *Shuai Ma* Responsible Science Editor: *Ling-Ling Wen*  
 Responsible Electronic Editor: *Xiao-Mei Zheng*  
 Proofing Editor-in-Chief: *Lian-Sheng Ma*

**NAME OF JOURNAL**  
*World Journal of Stomatology*

**ISSN**  
 ISSN 2218-6263 (online)

**LAUNCH DATE**  
 December 31, 2011

**FREQUENCY**  
 Quarterly

**EDITOR-IN-CHIEF**  
**Peter E Murray, BSc (Hons), PhD, Professor, Pathologist**, Department of Endodontics, College of Dental Medicine, Nova Southeastern University, 3200 South University Drive, Fort Lauderdale, FL 33328-2018, United States

**EDITORIAL OFFICE**  
 Jin-Lei Wang, Director  
 Xiu-Xia Song, Vice Director

*World Journal of Stomatology*  
 Room 903, Building D, Ocean International Center,  
 No. 62 Dongsihuan Zhonglu, Chaoyang District,  
 Beijing 100025, China  
 Telephone: +86-10-85381891  
 Fax: +86-10-85381893  
 E-mail: wjs@wjgnet.com  
 http://www.wjgnet.com

**PUBLISHER**  
 Baishideng Publishing Group Co., Limited  
 Flat C, 23/F, Lucky Plaza,  
 315-321 Lockhart Road, Wan Chai,  
 Hong Kong, China  
 Fax: +852-6555-7188  
 Telephone: +852-3177-9906  
 E-mail: bpgoffice@wjgnet.com  
 http://www.wjgnet.com

**PUBLICATION DATE**  
 February 20, 2013

**COPYRIGHT**  
 © 2013 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
 All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

**INSTRUCTIONS TO AUTHORS**  
 Full instructions are available online at [http://www.wjgnet.com/2218-6263/g\\_info\\_20100722180909.htm](http://www.wjgnet.com/2218-6263/g_info_20100722180909.htm)

**ONLINE SUBMISSION**  
<http://www.wjgnet.com/eps/>

## Risk aspects of dental restoratives: From amalgam to tooth-colored materials

Roland Frankenberger, Franklin Garcia-Godoy, Peter E Murray, Albert J Feilzer, Norbert Krämer

Roland Frankenberger, Department of Operative Dentistry and Endodontics, Dental School, University of Marburg and University Medical Center Giessen and Marburg, Campus Marburg, D-35039 Marburg, Germany

Franklin Garcia-Godoy, College of Dentistry, University of Tennessee, Knoxville, TN 38163, United States

Peter E Murray, Department of Endodontics, College of Dental Medicine, Nova Southeastern University, Fort Lauderdale, FL 33328-2018, United States

Albert J Feilzer, Department of Dental Materials Science, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam, NL-1066 EA Amsterdam, The Netherlands

Norbert Krämer, Department of Pediatric Dentistry, Dental School, University of Giessen and University Medical Center Giessen and Marburg, Campus Giessen, D-35392 Giessen, Germany

Author contributions: All the authors contributed to this article. Correspondence to: Roland Frankenberger, DMD, PhD, FICD, FADM, Professor and Chair, Department of Operative Dentistry and Endodontics, Dental School, University of Marburg and University Medical Center Giessen and Marburg, Campus Marburg, Georg-Voigt-Strasse 3, D-35039 Marburg, Germany. [frankbg@med.uni-marburg.de](mailto:frankbg@med.uni-marburg.de)

Telephone: +49-6421-5863240 Fax: +49-6421-5863745

Received: August 22, 2012 Revised: January 28, 2013

Accepted: February 5, 2013

Published online: February 20, 2013

its tooth-like appearance and more or less absence of extensive preparation rules. For many years it was believed that resin-based composites may cause pulpal injury. However, pulpal injury associated with the use of resin-based composites is not correlated with their cytotoxic properties. Nevertheless, resin-based composites and other dental materials require rigorous safety evaluation and continuous monitoring to prevent adverse events similar like with amalgam. Because of non-biocompatible pulp responses to resin-based composites and amalgam, they should not be placed in direct contact with the dental pulp. The less dentin remaining in the floor of preparations between resin-based composites or other dental materials is more likely to cause pulpitis. Percentage of patients and dental practitioners who display allergic reactions is between 0.7% and 2%. The release of cytotoxic monomers from resin-based materials is highest after polymerization and much lower after 1 wk. Substances released from resin-based composites have been shown to be toxic in cytotoxicity tests. Nevertheless, *in vitro* cytotoxicity assays have shown that amalgam has greater toxic effects than resin-based composites, sometime 100-700-fold higher. Altogether, the risk of side-effects is low, but not zero, especially for dental personnel.

© 2013 Baishideng. All rights reserved.

**Key words:** Exposures; Restoratives; Amalgam; Resin-based composites; Adhesives

Frankenberger R, Garcia-Godoy F, Murray PE, Feilzer AJ, Krämer N. Risk aspects of dental restoratives: From amalgam to tooth-colored materials. *World J Stomatol* 2013; 2(1): 1-11 Available from: URL: <http://www.wjgnet.com/2218-6263/full/v2/i1/1.htm> DOI: <http://dx.doi.org/10.5321/wjs.v2.i1.1>

### Abstract

Dental materials' choice of patients has considerably changed. Whereas cast gold and amalgam have been the predominant biomaterials for decades, today tooth-colored materials like resin-based composites and ceramics are more and more successful. However, are we going to replace a good but biologically questionable material (amalgam) with an equal material (resin composite) being more esthetic but also biologically questionable? For amalgam, long-term clinical studies reported some significant hints that in single cases amalgam may be a health hazard for patients, finally Norway banned amalgam completely. The main advantage of a resin-based composite over amalgam is

### INTRODUCTION

The choice of dental materials has considerably changed

during the last 20 years<sup>[1-3]</sup>. In former times, cast gold and amalgam have been the materials of choice for decades<sup>[4]</sup>. However, after amalgam was alleged to be inacceptably toxic and simultaneously esthetic demands of patients were growing, tooth-colored materials like resin-based composites and ceramics took more and more parts of this huge market<sup>[5]</sup>.

In terms of biocompatibility and exposure, cast gold may be still the best restorative material, however, it is non-esthetic when it is used in visible areas such as premolars and also here some health concerns in terms of gold allergies are present<sup>[6]</sup>. Furthermore, the gold price considerably increased from < \$ 200 to > \$ 1000 per ounce during the last decade which is consequently also transferred to restoration costs and therefore being detrimental for cost effectiveness as well. Other highly biocompatible materials like phosphate or glass ionomer cements are too brittle and therefore not able to withstand intraoral occlusal forces in deciduous and permanent teeth over time<sup>[1,2]</sup>.

Today's restorative trend clearly answers the question "black or white?" by more and more moving from metallic amalgam to resin-based composites<sup>[5]</sup>. The same is true for bonded all-ceramic restorations such as ceramic inlays and onlays, because they have to be adhesively luted with the same adhesives and resin-based composite luting cements. So we face the interesting question whether we are replacing a clinically good but biologically questionable material (amalgam) with an equal material being more esthetic (resin composite) but also (or even more?) biologically questionable.

## AMALGAM

Amalgam is one of the by far most successful dental restoratives which has been used all over the world since more than 150 years<sup>[7-10]</sup>. Long-term data are sufficient and long-term costs due to repair, refurbishment and tooth hard tissue loss during replacement are favourable<sup>[1-3,11-15]</sup>. Disadvantages are a compromised esthetic appearance due to an argentic to black color and especially biocompatibility concerns<sup>[7,16-24]</sup>. Dental silver amalgam consists of 50% mercury (in a complex mixture of copper, tin, silver, and zinc) and therefore this material was always suspected to be a considerable hazard for both patient and environment<sup>[25-35]</sup>.

In the literature of the field, two opposing groups are identified: Primarily toxicologists are arguing against the health risks of mercury vapor being released from amalgam restorations and potentially threatening health of both patients and dentists and moreover polluting the environment by dental mixing and application processes<sup>[25-50]</sup>. On the other hand many authors with clinical dental background repeatedly state that amalgam per se is one of the most successful restorative materials<sup>[3,5,8,11,13,14,23,24,51-65]</sup>. So what is the real threat with amalgam? It is common knowledge that high-dose exposure to elemental mercury vapor cause several diseases like

emotional dysfunction<sup>[53]</sup>. However, it is not fully understood to the date whether smaller amounts like being released from amalgam restorations are a considerable health hazard as well<sup>[51-53,66,67]</sup>.

In a retrospective cohort study involving 20 000 participants over 20 years (1977-1997) in the New Zealand defense force<sup>[28]</sup>. The cohort was linked with morbidity records by use of a time-varying exposure unit of 100 amalgam surface-years. Multiple sclerosis had an adjusted hazard ratio of 1.24, but there was no association with chronic fatigue syndrome (0.98), or kidney diseases<sup>[28]</sup>. Also Aminzadeh *et al*<sup>[25]</sup> reported some hints for a possible correlation of amalgam restorations and multiple sclerosis, however, also stating that more clinical studies are needed.

One of the most intensive clinical trials so far was the New England's Children Amalgam Trial (NECAT) giving clinical result. 534 children (6-10 years old) with carious primary molars received either amalgam or resin composite restorations. Evaluated parameters were neuropsychological outcome (Full-Scale IQ score, General Memory Index, Visual-Motor Composite of the Wide Range Assessment of Visual Motor Abilities) and renal glomerular function with no statistical differences between resin composite and amalgam groups in any of the investigated criteria<sup>[51,52,68]</sup>. Furthermore, parent-completed child behavior checklists and children's self-reports were collected. Children's psychosocial status was evaluated in relation to three indices of mercury exposure: treatment assignment, surface-years of amalgam, and urinary mercury excretion. Again, there was no evidence that exposure to mercury from dental amalgam was associated with adverse psychosocial outcomes<sup>[53]</sup>. In another part of NECAT, longitudinal amalgam exposure data in children randomized to amalgam restorations were analyzed. Amalgam and U-Hg were moderately correlated with the total of amalgam surfaces having been a good predictor of current U-Hg and posterior occlusal surface-years for cumulative U-Hg. One additional amalgam surface caused a 9% increase in current U-Hg, and one posterior occlusal surface-year resulted in a 3% increase in cumulative U-Hg excretion<sup>[61]</sup>. Finally it could be shown that daily chewing gum use resulted in higher urinary Hg levels<sup>[69]</sup>.

Halbach *et al*<sup>[56]</sup> measured internal exposure to amalgam-related mercury in plasma and erythrocytes after amalgam removal and estimated the amalgam-related absorbed dose in 82 patients. Post-removal steady-state Hg concentrations were taken for 18 mo for three groups: Removal of the fillings/removal and non-specific detoxification/health promotion program without removal. After amalgam removal, inorganic Hg was decreased, leveling at 27% of pre-removal levels after 60 d. Organic Hg in plasma did not change. Organic Hg in red cells of group A was lower in the early post-removal phase and higher in the late post-removal phase, being higher than the pre-removal control. A protracted increase in organic Hg was also found in red cells of group B after 60 d. In all groups, time profiles of urinary concentra-

tion and excretion of total-Hg were similar to those of inorganic-Hg levels in plasma. It was estimated that the amalgam-related inhalation and ingestion of Hg species were within the limits proposed by the World Health Organization (WHO), Agency for Toxic Substances and Disease Registry, and Environmental Protection Agency. The integrated daily Hg dose absorbed from amalgam was estimated < 3 µg for an average number of fillings and 7.4 µg for high amalgam load, with 30 µg being the tolerable dose according to the WHO<sup>[56]</sup>.

On the other hand, there is no doubt that amalgam restorations release small amounts of mercury during clinical service which is absorbed by several body tissues in human subjects<sup>[32-35,64,70-75]</sup>. The daily dose is found to be 14% of the threshold above which observable adverse neurological symptoms are expected<sup>[75]</sup>. It has reported that methyl mercury and inorganic mercury levels in blood and cortex of autopsy bodies with a significant correlation between methyl mercury in blood and occipital cortex. Inorganic mercury in blood and occipital cortex, as well as total-Hg in pituitary and thyroid were strongly associated with the number of dental amalgam surfaces at the time of death<sup>[46,67]</sup>. Mutter *et al.*<sup>[33]</sup> repeatedly stated that some of the clinical studies reporting low to no risk connected with dental amalgam may be methodically flawed which may lead to inadequate conclusions about the safety of dental amalgam. He also identified mercury vapor as potential reason for autism or Kawasaki's disease<sup>[34,35,76]</sup>. It is also controversially discussed whether carbamide peroxide tooth bleaching agents lead to an increased release of mercury<sup>[77,78]</sup>.

Another important point in the amalgam issue is occupational exposure for dentists and dental nurses<sup>[26,31,79-87]</sup>. It was found that a correlation between total Hg-U and duration of dental practice exists<sup>[87]</sup>. However, a cytogenetic damage in oral health professions dealing with amalgam was not reported<sup>[26,87]</sup>. Farahat *et al.*<sup>[82]</sup> showed that dental staff have significant exposure to mercury vapor, furthermore indicating a negative impact of mercury on thymus gland functions<sup>[82,87]</sup>. Jones *et al.*<sup>[84]</sup> investigated possible residual adverse effects from occupational mercury exposure in dentistry in 115 graduates of a dental nurse school from 1968-1971 because 30 years ago, dental nurses worked with amalgam without protective gloves or a ventilation system, resulting in chronic mercury exposure. Significant differences were found in current health experience and reproductive health, especially early hysterectomy experience. Reporting of Occupational Overuse Syndrome was strongly positively correlated with years of work.

Finally, also environmental aspects of mercury pollution by amalgam waste of dental practices and clinics have to be considered. Mercury occurs in nature as sulfides and in some minerals. All over the world every year 20 000-30 000 tons of mercury are discharged into the environment. Less than 50% of freshly triturated amalgam is inserted in cavities, more than 50% is waste. Extracted teeth with preexisting amalgams, amalgam-

contaminated capsules and cotton rolls are discharged with the solid waste. However, dental mercury contamination makes only 3%-4% of global mercury being insignificant compared with industrial pollution<sup>[50,80,88,89]</sup>. With proper amalgam separators it could be even more reduced<sup>[30,80,88,89]</sup>.

Despite all hints towards side-effects caused by mercury vapor of dental amalgam restorations, unproportionally many patients suffer amalgam incompatibility. Gottwald *et al.*<sup>[55]</sup> conducted an interdisciplinary case-control study with special focus on toxicological, allergic, psychological and psychiatric aspects. Patients with amalgam-associated complaints ( $n = 40$ ) were compared to amalgam bearers without complaints ( $n = 40$ ) regarding quantity, surface area and quality of amalgam fillings, mercury load in blood and urine, allergy examination, and psychometric assessment with questionnaires noting coping strategies, interpersonal problems and self-consciousness. Patients and controls did not reveal different mercury concentrations in body fluids with patients having higher levels of psychic distress, higher incidence of depression and somatization disorders as well as different styles of coping with anxiety compared to controls. So the theory of amalgam-related complaints as an expression of underlying psychic problems was confirmed. A socio-economically important issue is that a ban of dental amalgam would also have some economic impact. Beazoglou *et al.*<sup>[90]</sup> calculated the economic costs of an amalgam ban in the United States with total expenditures for restorations increasing from \$ 46.2 billion to \$ 49.7 billion and with consequently 15 444 021 fewer restorations inserted per year. An estimated first-year impact of an amalgam ban means an increase in expenditures of \$ 8.2 billion.

Altogether it can be summarized that long-term clinical studies primarily demonstrated that amalgam can be safely used for patients, dental staff, and environment. However, there are some significant hints that in single cases amalgam may be a health hazard for patients. From 2008, Norway banned amalgam completely which is another hint<sup>[58]</sup>. So, amalgam remains an excellent restorative material with centuries of clinical success and decades of significant problems in biocompatibility.

## RESIN-BASED COMPOSITES

A remarkable change in restorative dentistry has been the dramatic drop in the use of amalgam to restore teeth<sup>[91]</sup>. Patient and practitioner demand for a tooth-colored material as an alternative to amalgam was addressed in 1955 by Dr. Buonocore who described the use of a plastic material to restore teeth<sup>[92]</sup>. Later in 1950s, the first tooth-colored direct restorative material called Sevitrone was produced by L.D. Caulk<sup>[93]</sup>. In the 1960s, several resin-based composite dental restorative materials (resin-based composites) were introduced<sup>[94]</sup>. The main advantage of a resin-based composite over amalgam is that it can be made in a wide range of tooth colors allowing the almost invisible restoration of teeth. However, the benefits of

resin-based composites in comparison with amalgam and other dental materials have proved to be controversial. Normally resin-based composites can be used to restore teeth and repair or replace failing restorations with less removal of vital tooth structure in comparison with amalgam<sup>[95]</sup>.

Unlike amalgam, resin-based composites must be bonded to teeth using an adhesive, which makes them more expensive and more technique-sensitive. Without meticulous placement, resin-based composite restorations can fail quickly. Nevertheless, even with the most meticulous placement, the longevity of resin-based composite restorations placed in posterior teeth has been shown to be significantly less than amalgam restorations<sup>[96]</sup>. The main reasons for the inferior clinical longevity of composite restorations in comparison with amalgam are marginal discoloration and a loss of adhesion<sup>[97]</sup>.

Resin-based composites shrink by approximately 5% upon light-curing, which can create gaps for bacterial microleakage along the cavity margins<sup>[98]</sup>. These examples indicate that many of the problems patients have suffered with resin-based composites does not appear to be directly caused by the chemicals within the formulation of the material, but because of the shortcomings of the material when it is used to restore teeth. The shortcomings of resin-based composites, particularly their polymerization shrinkage, are an active area of research and new lower shrinkage materials are under development to help improve their clinical performance similar to amalgam restorations.

The earliest resin-based composites had the worst longevity because they were prone to breakage and leakage due to their weak compressive strength<sup>[99]</sup>. The initial techniques to etch enamel to bond dental restorations were also not very successful, so many restorations suffered a loss of adhesion and were lost<sup>[100]</sup>. Many clinicians were initially reluctant to bond to dentin because they feared the high acid content of the etchant would cause a necrosis of underlying pulp tissue<sup>[101]</sup>. Subsequently, it was discovered that the buffering capacity of dentin, along with an improved quality of sealing to reduce microleakage, reduced the pulp irritation beneath resin-based composite restorations<sup>[102]</sup>. As research progressed, the concept of the “hybrid layer” was created to explain the physical and chemical interactions of the adhesive, resin-based composite, and tooth structure<sup>[103]</sup>. The “hybrid layer” concept has proved to be useful to develop research strategies to increase the quality of sealing and bonding of resin-based composites to tooth structure<sup>[104]</sup>. Improvements to the process of accomplishing resin-based composite bonding to tooth structure progressed through a number of “generations”. Each new generation of resin-based composite materials have had improved bonding and physical properties which are beneficial to patients through their increased longevity<sup>[105]</sup>. The current, 7<sup>th</sup> generation of resin-based composite adhesives can accomplish very high bond strengths to tooth structure<sup>[106]</sup>. The newest generations of “one-step”

resin-based composite materials are generally easier for practitioners to use, and help reduce the exposure of patients to failed restorations.

For many years it was believed that the toxicity of the chemicals in the resin-based composite materials was responsible for pulpal injury. However, pulpal injury associated with the use of resin-based composites could not be correlated with their cytotoxic properties<sup>[107]</sup>. The discovery of the effect of bacterial contamination on the vitality of the tooth pulp, was a major milestone in dental research. In general, resin-based composites and other dental materials do not provide a hermetic seal with the tooth structure. Bacterial leakage may subsequently occur. The presence of bacteria and their toxic products can evoke an inflammatory response in the underlying pulp. Suh *et al*<sup>[108]</sup> demonstrated that the growth of bacteria in cavity restorations was directly correlated with pulpal inflammatory responses in the adjacent pulp tissue. As yet no permanent filling material has shown to consistently provide a perfect marginal seal, so leakage and bacterial contamination are always a threat to the integrity of the pulp. Therefore, the antibacterial properties of restorative materials are of considerable importance, and this explains the clinical success of some cytotoxic restorative materials, such as zinc oxide eugenol<sup>[109]</sup>. Despite these findings, it must be acknowledged that generally it is preferable to use dental materials which have the least potential to be toxic to patients and dental professionals. Similar to amalgam, resin-based composites and other dental materials require rigorous safety evaluation and continuous monitoring<sup>[110]</sup> to prevent adverse events.

Dentin and enamel have different physical properties and elemental compositions which have complicated the resin-based composite bonding to tooth structure<sup>[111]</sup>. It was discovered that the inclusion of hydrophobic monomers in adhesives could not penetrate the aqueous environment of demineralized dentin. Thus, methacrylate-based priming agents were used to create a permeable interface for the formation of a hybrid layer<sup>[112]</sup> which can increase micromechanical retention of the resin-based composite<sup>[113]</sup>. Thus, the need for “wet bonding” arose, and techniques for preparing the interface for increasingly hydrophobic monomers were developed<sup>[114]</sup>. Wet bonding systems have been successful<sup>[115]</sup>. However, they require the handling of multiple components which must be used in multiple steps. To facilitate the ease and speed with which bonding can be accomplished, the latest generation of “one-step adhesive systems” have been introduced which don’t have a separate acid etching step. Instead, acrylic resin monomers themselves provide the acidity needed for demineralization and simultaneously penetrate exposed and uplifted collagen fibrils<sup>[116]</sup>. A dental composite typically consists of a resin-based oligomer matrix, such as a bisphenol A-glycidyl methacrylate (Bis-GMA) or urethane dimethacrylate (UDMA), and an inorganic filler such as silicon dioxide silica. Compositions vary widely, with proprietary mixes of resins forming the matrix, as well as engineered filler glasses and glass

ceramics. The filler gives the composite wear resistance and translucency. A coupling agent such as silane is used to enhance the bond between these two components. An initiator package (such as: Camphorquinone, Phenylpropanedion or Lucirin) begins the polymerization reaction of the resins. A catalyst is added in varying concentrations to control the speed of polymerization<sup>[117]</sup>. Resin-based composite materials are all capable of causing moderate to severe cytotoxicity when placed in contact with *in vitro* cell lines<sup>[118]</sup>. Resin-based composite materials may also cause severe pulp necrosis when used for direct-pulp capping<sup>[119]</sup>. The migration of adhesive and resin-based composite particles into pulp tissue can stimulate inflammatory responses<sup>[120]</sup>. Because of these non-biocompatible pulp responses to resin-based composites and amalgam, they should not be placed in direct contact with the dental pulp. A biocompatible liner such as Ca(OH)<sub>2</sub> or preferably; mineral trioxide aggregate (MTA) must be used as a liner to help prevent unfavorable responses to direct pulp capping with resin-based composite<sup>[121]</sup> or amalgam. An MTA or Ca(OH)<sub>2</sub> liner is not needed in shallow indirect pulp capping restorations because the buffering effect of dentin can prevent the diffusion of chemicals from resin-based composites and amalgam from entering the pulp tissue, particularly when the dentin thickness is above 0.5 mm<sup>[122]</sup>. The less dentin remaining in the floor of preparations between resin-based composites or other dental materials is more likely to cause pulpitis<sup>[122]</sup>.

A number of local and systemic reactions to resin-based composite materials have been reported. The incidence of patients and dental practitioners who display allergic reactions is between 0.7% and 2%<sup>[123-126]</sup>. The main source of cellular and molecular cytotoxic injury from resin-based materials is claimed to be the leaching of un-polymerized monomers from the restoration during and after polymerization<sup>[127]</sup> which can reduce pulp vitality and cause a retraction of the gingival margin<sup>[128,129]</sup>. The release of cytotoxic monomers from resin-based materials is highest after polymerization and much lower after 1 wk<sup>[130]</sup>. Which may suggest the health risks to patients and practitioners are highest when in contact with newly polymerized resin-based composite materials, and the health risk diminishes over time.

Erosion and saliva degradation of resin-based composites may cause the release of leachable substances. Human-saliva derived esterases can biodegrade resin-based composites, causing the release of (Bis-GMA) monomers and (UDMA-type) comonomer<sup>[131]</sup>. The substances released from resin-based composites, particularly the (Bis-GMA) monomers have been shown to be toxic in cytotoxicity tests<sup>[132]</sup>. The presence of leached compounds is dependent on the formulation of resin-based composite<sup>[133]</sup>. The more flowable resin-based composites are more toxic than the traditional resin-based composites<sup>[134]</sup>. The relative *in vitro* cytotoxicity of resin-based composite monomers measured using a bromodeoxyuridine assay discovered that the Hg<sup>2+</sup> amalgam component was four-

fold more toxic than Bis-GMA to human gingival fibroblasts<sup>[135]</sup>. Almost all the *in vitro* cytotoxicity assays have shown that amalgam has greater toxic effects than resin-based composites, sometime 100-700-fold higher<sup>[136]</sup>. A problem is the general lack of resin-based composite biocompatibility data in comparison with amalgam. The results from systemic toxicity tests of resin-based composites do not indicate any unacceptable risk to the patient's general health<sup>[137]</sup>. The *in vitro* screening of some components of resin-based composites are mutagenic<sup>[138]</sup>. Due to the limitations of the *in vitro* genotoxicity test systems and the comparatively high concentrations needed to elicit the reactions, no unacceptable risk can yet be derived from those data for the patient<sup>[139]</sup>. Most of the available data suggests that amalgam is relatively more hazardous to patients and dental professionals, than resin-based composites.

Skin and mucosa which come into contact with resin-based composites and bonding agents can become slightly inflamed which is commonly observed as a reddening of the affected area. However, if a patient or dental professional is allergic to a compound within the resin-based composite their reactions may be more severe and allergic irritant contact dermatitis can be observed. Contact urticaria, pigmentary changes, and photoallergic contact dermatitis may occasionally occur. Rarely other health effects, such as respiratory and neurologic signs and symptoms have been reported, but none have been linked to dental resin-based composites<sup>[140]</sup>. The concentrations are probably too minute to cause systemic reactions<sup>[137]</sup>. The most common resin-based composites to cause contact dermatitis, are (meth)acrylics, polyurethanes, phenol-formaldehydes, polyesters, amino resins (melamine-formaldehydes, urea-formaldehydes), polyvinyls, polystyrenes, polyolefins, polyamides and polycarbonates<sup>[140]</sup>. Contact dermatitis usually presents on the hands, fingers, and forearms, while facial, eyelid, and neck involvement may occur through indirect contact, *e.g.*, *via* the hands, or from airborne exposure<sup>[140]</sup>. Patch testing with commercially available materials is important for a diagnosis of an allergy<sup>[141]</sup>. In some countries, occupational dermatoses are relatively common among dental staff, sometimes entailing occupational disability and re-schooling<sup>[142]</sup>. The risk of occupational dermatoses can be reduced by the development of new bonding techniques and careful risk-benefit assessments in the formulation of new dental composites. To protect patients from potential hazards of light-cured monomers released from resin-based composites it is important to use an effective curing unit and to applying the light-curing for the recommended length of time<sup>[142]</sup>. To protect dental professionals from the potential hazards of monomers released from resin-based composites, gloves should always be worn to prevent direct skin contact.

---

## THE RISK ASPECT IN RESTORATIVE DENTISTRY

---

Dental restorative materials represent the most frequent

replacement materials in the human body<sup>[143]</sup>. Despite that fact, biocompatibility issues regarding dental materials (especially amalgam) have not been scientifically evaluated until the early 1980s<sup>[141]</sup>. During the last two decades, however, amalgam lost its unique feature because adhesively bonded resin composites got suitable even for stress-bearing posterior restorations<sup>[144]</sup>. The paradigm shift towards minimally invasive restorations additionally supported this trend<sup>[145]</sup>. However, in many cases there is almost no patient or dental staff knowledge of hazards by the use of dental restoratives<sup>[146]</sup>. Furthermore it is of significant interest whether recently used dental materials changed the use-risk ratio.

Fundamental judgement tool of dental materials is a risk analysis. Schmalz *et al*<sup>[145]</sup> defined the term “risk” concerning biocompatibility of dental restoratives as “the probability of a side effect and the severity of that side effect”. Risk analysis implies the description of indication ranges of a medical product, analysis of tissue exposure, and potential hazard<sup>[147]</sup>. So risk analyses try to determine the probability and severity of side effects for human health by exact knowledge of their composition. The consecutive risk assessment clarifies under estimation of usefulness and risk, whether a medical product may enter the market. Here it is decisive to compare the advantages of the material with the frequency and severity of side-effects<sup>[148]</sup>. In restorative dentistry, primarily a potential hazard by release of ingredients is discussed. Dental biomaterials are medical products with medium hazard potential. This means that clinical investigations are not mandatory in Europe, manufacturers just have to meet minimum requirements<sup>[147]</sup>. Especially in the post-amalgam era in the middle of the 1990s, some restoratives diminished from the market because minimum requirements were not achieved (Figure 1)<sup>[149]</sup>.

Systematic epidemiological studies concerning frequency of side-effects with dental biomaterials are missing. Mjör<sup>[147]</sup> reported possible side-effects with different materials with 13 325 sessions (done by 137 dentists) and 24 cases of subjective discomfort, 7 cases of acute nature, and 15 cases of long-standing effects. In eight cases, amalgam was the reason for patients’ complaints<sup>[150]</sup>. So altogether the risk of side-effects is low, but not zero<sup>[148]</sup>.

Dental personnel is much more under risk than patients. Geukens *et al*<sup>[148]</sup> observed 13 000 patients with contact dermatitis. In 31 patients (meth) acrylates were responsible for the complaints, and almost 50% of these group was working as dentist or dental nurse or dental technician<sup>[151]</sup>. Unfortunately, latex or vinyl gloves do not guarantee for safety due to their permeability at least after some minutes. This should be one of the reasons that dental personnel reveal increased rates of contact dermatitis of the fingers or allergic reactions following contact with monomers<sup>[152-154]</sup>. Thus, it is clearly recommended to completely avoid contact with unpolymerized resins<sup>[147]</sup>.

Side-effects of dental materials are primarily of a local nature (*e.g.*, gingivitis, mucosal alterations, pulpitis, *etc.*) or allergic (type I: immediate reaction or type IV: delayed reaction). Contact allergies have been observed for nickel



**Figure 1 Some restoratives diminished from the market.** A: Ariston restoration in lower second premolar at baseline; B: Due to a 2% linear expansion, 18 mo of clinical service were enough to disrupt the lingual cusp.



**Figure 2 Fracture of a ceramic inlay in an upper first premolar.**

sulfate, potassium dichromate, cobalt chloride, palladium chloride and gold sodium thiosulfate in patients with presence of metal allergy<sup>[155]</sup>.

Other systemic effects (*e.g.*, mutagenic, cancerogenic or teratogenic) are more of a theoretical nature<sup>[147]</sup>. Although there is a proven amount of substance release, this does not automatically mean an unacceptable health hazard<sup>[137]</sup>. Bacsik *et al*<sup>[156]</sup> could show estrogenic effects by bisphenol-A in mice, however, it is a matter of clinical relevance when substances are directly injected into the stomach of the animals instead of investigating true release from restorations. So also here clinical studies remain the ultimate instrument for risk assessment<sup>[157]</sup>. In the course of prospective clinical studies with dental

biomaterials, the risk aspect plays a minor role. Main focus here are longevity aspects such as marginal integrity, restoration integrity, hypersensitivities, and recurrent caries. Moreover, patient numbers in dentistry *e.g.*, for studies with posterior restorations are normally in the range of 30 patients<sup>[158]</sup> which may not be of sufficient power to describe side-effects. This is clearly reflected by evaluations of side-effects with local anesthesia. Despite 0.5 million local anesthetic injections which are administered in the United States daily, the actual risks of toxicity from these local anesthetic injections remain more or less unknown<sup>[159]</sup>. Therefore, prospective clinical studies mainly concentrate on local risks such as pulp reactions, compatibility with gingiva/periodontium, irritation of the oral mucosa, or biofilm accumulation<sup>[157]</sup>.

The benefit of dental biomaterials is still related to longevity. Kaplan-Meier survival curves and the associated nonparametric log rank test statistic are methods of choice for estimation of survival and therefore also failure risk<sup>[159]</sup>. This risk is appropriately reflected by annual failure rates<sup>[160,161]</sup>. Quality assessment of dental restorations is carried out according to modified USPHS criteria with clinical examinations and analysis of replicas<sup>[162]</sup>. Main failure reasons are related to crucial criteria “marginal quality”, “restoration integrity”, “tooth integrity”, and “hypersensitivities” (Figure 2)<sup>[162]</sup>. Concerning clinical success, ADA criteria of 1996 are still valid. Failure rates < 10% after 4 years are defined as acceptable.

## REFERENCES

- Hickel R, Kaaden C, Paschos E, Buerkle V, García-Godoy F, Manhart J. Longevity of occlusally-stressed restorations in posterior primary teeth. *Am J Dent* 2005; **18**: 198-211 [PMID: 16158813]
- Manhart J, Chen H, Hamm G, Hickel R. Buonocore Memorial Lecture. Review of the clinical survival of direct and indirect restorations in posterior teeth of the permanent dentition. *Oper Dent* 2004; **29**: 481-508 [PMID: 15470871]
- Mjör IA, Moorhead JE, Dahl JE. Selection of restorative materials in permanent teeth in general dental practice. *Acta Odontol Scand* 1999; **57**: 257-262 [PMID: 10614902 DOI: 10.1080/000163599428661]
- Erpenstein H, Kerschbaum T, Halfin T. Long-term survival of cast-gold inlays in a specialized dental practice. *Clin Oral Investig* 2001; **5**: 162-166 [PMID: 11642560 DOI: 10.1007/s007840100119]
- De Moor R, Delmé K. [Black or white--Which choice for the molars? Part 2. Which does one choose for the restoration of posterior teeth: amalgam or composite?]. *Rev Belge Med Dent* (1984) 2008; **63**: 135-146 [PMID: 19227687]
- Ahnlide I, Ahlgren C, Björkner B, Bruze M, Lundh T, Möller H, Nilner K, Schütz A. Gold concentration in blood in relation to the number of gold restorations and contact allergy to gold. *Acta Odontol Scand* 2002; **60**: 301-305 [PMID: 12418721 DOI: 10.1080/00016350260248283]
- Osborne JW. Safety of dental amalgam. *J Esthet Restor Dent* 2004; **16**: 377-388 [PMID: 15801343 DOI: 10.1111/j.1708-8240.2004.tb00072.x]
- Smith D. Mercury pollution: fact or fiction? *J Okla Dent Assoc* 2004; **95**: 5 [PMID: 15508975]
- Kostyniak PJ. Mercury and dentistry. *Alpha Omegan* 2003; **96**: 53-56 [PMID: 14983731]
- Soler JJ, Ellacuria J, Triana R, Guinea E, Osborne JW. A history of dental amalgam. *J Hist Dent* 2002; **50**: 109-116 [PMID: 12413157]
- Fuks AB. Status of amalgams in pediatric dentistry: pros and cons. *Alpha Omegan* 2005; **98**: 26-32 [PMID: 16381440]
- Maserejian NN, Tavares MA, Hayes C, Soncini JA, Trachtenberg FL. Prospective study of 5-year caries increment among children receiving comprehensive dental care in the New England children's amalgam trial. *Community Dent Oral Epidemiol* 2009; **37**: 9-18 [PMID: 18782333 DOI: 10.1111/j.1600-0528.2008.00437.x]
- Sjögren P, Halling A. Survival time of Class II molar restorations in relation to patient and dental health insurance costs for treatment. *Swed Dent J* 2002; **26**: 59-66 [PMID: 12462873]
- Sjögren P, Halling A. Long-term cost of direct Class II molar restorations. *Swed Dent J* 2002; **26**: 107-114 [PMID: 12425224]
- Trachtenberg F, Maserejian NN, Tavares M, Soncini JA, Hayes C. Extent of tooth decay in the mouth and increased need for replacement of dental restorations: the New England Children's Amalgam Trial. *Pediatr Dent* 2008; **30**: 388-392 [PMID: 18942597]
- Nur Ozdabak H, Karaođlanoglu S, Akgül N, Polat F, Seven N. The effects of amalgam restorations on plasma mercury levels and total antioxidant activity. *Arch Oral Biol* 2008; **53**: 1101-1106 [PMID: 18790473 DOI: 10.1016/j.archoralbio.2008.05.012]
- Osborne JW. Dental amalgam is 50% mercury ... or is it? *Oper Dent* 2005; **30**: 274 [PMID: 15986944]
- Puriene A, Janulyte V, Musteikyte M, Bendinskaite R. General health of dentists. Literature review. *Stomatologija* 2007; **9**: 10-20 [PMID: 17449973]
- St John KR. Biocompatibility of dental materials. *Dent Clin North Am* 2007; **51**: 747-760, viii [PMID: 17586154 DOI: 10.1016/j.cden.2007.03.003]
- Sweeney M, Creanor SL, Smith RA, Foye RH. The release of mercury from dental amalgam and potential neurotoxicological effects. *J Dent* 2002; **30**: 243-250 [PMID: 12450715 DOI: 10.1016/S0300-5712(02)00040-4]
- Udoye C, Aguwa E. Amalgam safety and dentists' attitude: a survey among a Subpopulation of Nigerian dentists. *Oper Dent* 2008; **33**: 467-471 [PMID: 18666507 DOI: 10.2341/07-123]
- van Zyl I. Mercury amalgam safety: a review. *J Mich Dent Assoc* 1999; **81**: 40-48, 50, 52 [PMID: 10686928]
- Wahl MJ. Amalgam--Resurrection and redemption. Part 1: the clinical and legal mythology of anti-amalgam. *Quintessence Int* 2001; **32**: 525-535 [PMID: 11495565]
- Yip HK, Li DK, Yau DC. Dental amalgam and human health. *Int Dent J* 2003; **53**: 464-468 [PMID: 14725374 DOI: 10.1002/j.1875-595X.2003.tb00888.x]
- Aminzadeh KK, Etminan M. Dental amalgam and multiple sclerosis: a systematic review and meta-analysis. *J Public Health Dent* 2007; **67**: 64-66 [PMID: 17436982 DOI: 10.1111/j.1752-7325.2007.00011.x]
- Atesagaoglu A, Omurlu H, Ozcagli E, Sardas S, Ertas N. Mercury exposure in dental practice. *Oper Dent* 2006; **31**: 666-669 [PMID: 17153974 DOI: 10.2341/05-128]
- Balevi B. Are dental amalgams toxic to children? Comment on 2 recently published randomized controlled trials. *J Can Dent Assoc* 2007; **73**: 51-54 [PMID: 17295944]
- Bates MN, Fawcett J, Garrett N, Cutress T, Kjellstrom T. Health effects of dental amalgam exposure: a retrospective cohort study. *Int J Epidemiol* 2004; **33**: 894-902 [PMID: 15155698 DOI: 10.1093/ije/dyh164]
- Bates MN. Mercury amalgam dental fillings: an epidemiologic assessment. *Int J Hyg Environ Health* 2006; **209**: 309-316 [PMID: 16448848 DOI: 10.1016/j.ijheh.2005.11.006]
- Hiltz M. The environmental impact of dentistry. *J Can Dent Assoc* 2007; **73**: 59-62 [PMID: 17295946]
- Hörsted-Bindslev P. Amalgam toxicity--environmental and occupational hazards. *J Dent* 2004; **32**: 359-365 [PMID: 15193783 DOI: 10.1016/j.jdent.2004.02.002]

- 32 **Mutter J**, Naumann J. Mercury and the risk of myocardial infarction. *N Engl J Med* 2003; **348**: 2151-2154; author reply 2151-2154 [PMID: 12765162 DOI: 10.1056/NEJM200305223482119]
- 33 **Mutter J**, Naumann J, Sadaghiani C, Walach H, Drasch G. Amalgam studies: disregarding basic principles of mercury toxicity. *Int J Hyg Environ Health* 2004; **207**: 391-397 [PMID: 15471104 DOI: 10.1078/1438-4639-00305]
- 34 **Mutter J**, Naumann J, Schneider R, Walach H, Haley B. Mercury and autism: accelerating evidence? *Neuro Endocrinol Lett* 2005; **26**: 439-446 [PMID: 16264412]
- 35 **Mutter J**, Yeter D. Kawasaki's disease, acrodynia, and mercury. *Curr Med Chem* 2008; **15**: 3000-3010 [PMID: 19075648 DOI: 10.2174/092986708786848712]
- 36 **af Geijersstam E**, Sandborgh-Englund G, Jonsson F, Ekstrand J. Mercury uptake and kinetics after ingestion of dental amalgam. *J Dent Res* 2001; **80**: 1793-1796 [PMID: 11926235]
- 37 **Barregard L**. Mercury from dental amalgam: looking beyond the average. *Occup Environ Med* 2005; **62**: 352-353 [PMID: 15901879 DOI: 10.1136/oem.2004.018911]
- 38 **Barregard L**. Exposure to inorganic mercury: from dental amalgam to artisanal gold mining. *Environ Res* 2008; **107**: 4-5 [PMID: 18384768 DOI: 10.1016/j.envres.2008.02.006]
- 39 **Barregard L**, Trachtenberg F, McKinlay S. Renal effects of dental amalgam in children: the New England children's amalgam trial. *Environ Health Perspect* 2008; **116**: 394-399 [PMID: 18335109 DOI: 10.1289/ehp.10504]
- 40 **Clarkson TW**, Magos L. The toxicology of mercury and its chemical compounds. *Crit Rev Toxicol* 2006; **36**: 609-662 [PMID: 16973445 DOI: 10.1080/10408440600845619]
- 41 **Clarkson TW**, Vyas JB, Ballatori N. Mechanisms of mercury disposition in the body. *Am J Ind Med* 2007; **50**: 757-764 [PMID: 17477364 DOI: 10.1002/ajim.20476]
- 42 **Edlich RF**, Greene JA, Cochran AA, Kelley AR, Gubler KD, Olson BM, Hudson MA, Woode DR, Long WB, McGregor W, Yoder C, Hopkins DB, Saepoff JP. Need for informed consent for dentists who use mercury amalgam restorative material as well as technical considerations in removal of dental amalgam restorations. *J Environ Pathol Toxicol Oncol* 2007; **26**: 305-322 [PMID: 18197828 DOI: 10.1615/JEnvironPatholToxicolOncol.v26.i4.70]
- 43 **Edlich RF**, Cross CL, Dahlstrom JJ, Long WB, Newkirk AT. Implementation of revolutionary legislation for informed consent for dental patients receiving amalgam restorations. *J Environ Pathol Toxicol Oncol* 2008; **27**: 1-3 [PMID: 18551891 DOI: 10.1615/JEnvironPatholToxicolOncol.v27.i1.10]
- 44 **Edlich RF**, Cochran AA, Cross CL, Wack CA, Long WB, Newkirk AT. Legislation and informed consent brochures for dental patients receiving amalgam restorations. *Int J Toxicol* 2008; **27**: 313-316 [PMID: 18821394 DOI: 10.1080/10915810802366851]
- 45 **Guzzi G**, Minoia C, Pigatto PD, Severi G. Methylmercury, amalgams, and children's health. *Environ Health Perspect* 2006; **114**: A149; author reply A149-A150 [PMID: 16507443 DOI: 10.1289/ehp.114.a149a]
- 46 **Guzzi G**, Grandi M, Cattaneo C, Calza S, Minoia C, Ronchi A, Gatti A, Severi G. Dental amalgam and mercury levels in autopsy tissues: food for thought. *Am J Forensic Med Pathol* 2006; **27**: 42-45 [PMID: 16501347 DOI: 10.1097/01.paf.0000201177.62921.c8]
- 47 **Guzzi G**, Pigatto PD. Occupational exposure to mercury from amalgams during pregnancy. *Occup Environ Med* 2007; **64**: 715-716; discussion 715-716 [PMID: 17881473 DOI: 10.1136/oem.2007.032789]
- 48 **Guzzi G**, Minoia C. Biological detoxification and mercury dental amalgam. *J Dent Res* 2008; **87**: 800 [PMID: 18719204 DOI: 10.1177/154405910808700912]
- 49 **Guzzi G**, Fogazzi GB, Cantù M, Minoia C, Ronchi A, Pigatto PD, Severi G. Dental amalgam, mercury toxicity, and renal autoimmunity. *J Environ Pathol Toxicol Oncol* 2008; **27**: 147-155 [PMID: 18540850 DOI: 10.1615/JEnvironPatholToxicolOncol.v27.i2.70]
- 50 **Guzzi G**, Pigatto PD. Urinary mercury levels in children with amalgam fillings. *Environ Health Perspect* 2008; **116**: A286-A287 [PMID: 18629336 DOI: 10.1289/ehp.11235]
- 51 **Bellinger DC**, Trachtenberg F, Daniel D, Zhang A, Tavares MA, McKinlay S. A dose-effect analysis of children's exposure to dental amalgam and neuropsychological function: the New England Children's Amalgam Trial. *J Am Dent Assoc* 2007; **138**: 1210-1216 [PMID: 17785386]
- 52 **Bellinger DC**, Daniel D, Trachtenberg F, Tavares M, McKinlay S. Dental amalgam restorations and children's neuropsychological function: the New England Children's Amalgam Trial. *Environ Health Perspect* 2007; **115**: 440-446 [PMID: 17431496 DOI: 10.1289/ehp.9497]
- 53 **Bellinger DC**, Trachtenberg F, Zhang A, Tavares M, Daniel D, McKinlay S. Dental amalgam and psychosocial status: the New England Children's Amalgam Trial. *J Dent Res* 2008; **87**: 470-474 [PMID: 18434579 DOI: 10.1177/154405910808700504]
- 54 **Giangregio E**. Amalgam: has junk science caused dentists to pull it? *CDS Rev* 2006; **99**: 10-13 [PMID: 16903498]
- 55 **Gottwald B**, Kupfer J, Traenckner I, Ganss C, Gieler U. Psychological, allergic, and toxicological aspects of patients with amalgam-related complaints. *Psychother Psychosom* 2002; **71**: 223-232 [PMID: 12097788 DOI: 10.1159/000063648]
- 56 **Halbach S**, Vogt S, Köhler W, Felgenhauer N, Welzl G, Kremers L, Zilker T, Melchart D. Blood and urine mercury levels in adult amalgam patients of a randomized controlled trial: interaction of Hg species in erythrocytes. *Environ Res* 2008; **107**: 69-78 [PMID: 17767927 DOI: 10.1016/j.envres.2007.07.005]
- 57 **Hyson JM**. Amalgam: Its history and perils. *J Calif Dent Assoc* 2006; **34**: 215-229 [PMID: 16895078]
- 58 **Jones DW**. A Scandinavian tragedy. *Br Dent J* 2008; **204**: 233-234 [PMID: 18327185 DOI: 10.1038/bdj.2008.151]
- 59 **Jones DW**. Has dental amalgam been torpedoed and sunk? *J Dent Res* 2008; **87**: 101-102 [PMID: 18218833 DOI: 10.1177/154405910808700203]
- 60 **Martin MD**, Woods JS. The safety of dental amalgam in children. *Expert Opin Drug Saf* 2006; **5**: 773-781 [PMID: 17044804 DOI: 10.1517/14740338.5.6.773]
- 61 **Maserejian NN**, Trachtenberg FL, Assmann SF, Barregard L. Dental amalgam exposure and urinary mercury levels in children: the New England Children's Amalgam Trial. *Environ Health Perspect* 2008; **116**: 256-262 [PMID: 18288327 DOI: 10.1289/ehp.10440]
- 62 **Maserejian NN**, Tavares MA, Hayes C, Soncini JA, Trachtenberg FL. Rural and urban disparities in caries prevalence in children with unmet dental needs: the New England Children's Amalgam Trial. *J Public Health Dent* 2008; **68**: 7-13 [PMID: 18179469 DOI: 10.1111/j.1752-7325.2007.00057.x]
- 63 **Mitchell RJ**, Koike M, Okabe T. Posterior amalgam restorations--usage, regulation, and longevity. *Dent Clin North Am* 2007; **51**: 573-589, v [PMID: 17586144 DOI: 10.1016/j.cden.2007.04.004]
- 64 **Needleman HL**. Mercury in dental amalgam--a neurotoxic risk? *JAMA* 2006; **295**: 1835-1836 [PMID: 16622146 DOI: 10.1001/jama.295.15.1835]
- 65 **Wahl MJ**. Amalgam--resurrection and redemption. Part 2: The medical mythology of anti-amalgam. *Quintessence Int* 2001; **32**: 696-710 [PMID: 11695138]
- 66 **Berglund A**. Release of mercury vapor from dental amalgam. *Swed Dent J Suppl* 1992; **85**: 1-52 [PMID: 1475757]
- 67 **Björkman L**, Lundekvam BF, Laegreid T, Bertelsen BI, Morild I, Lilleng P, Lind B, Palm B, Vahter M. Mercury in human brain, blood, muscle and toenails in relation to exposure: an autopsy study. *Environ Health* 2007; **6**: 30 [PMID: 17931423 DOI: 10.1186/1476-069X-6-30]
- 68 **Bellinger DC**, Trachtenberg F, Barregard L, Tavares M, Cer-

- nichiari E, Daniel D, McKinlay S. Neuropsychological and renal effects of dental amalgam in children: a randomized clinical trial. *JAMA* 2006; **295**: 1775-1783 [PMID: 16622139 DOI: 10.1001/jama.295.15.1775]
- 69 **Dunn JE**, Trachtenberg FL, Barregard L, Bellinger D, McKinlay S. Scalp hair and urine mercury content of children in the Northeast United States: the New England Children's Amalgam Trial. *Environ Res* 2008; **107**: 79-88 [PMID: 17961541 DOI: 10.1016/j.envres.2007.08.015]
- 70 **Larose P**, Basciano M. Dental mercury and Norway. *J Dent Res* 2008; **87**: 413; author reply 413 [PMID: 18434570 DOI: 10.1177/154405910808700512]
- 71 **Leistevuo J**, Leistevuo T, Helenius H, Pyy L, Osterblad M, Huovinen P, Tenovou J. Dental amalgam fillings and the amount of organic mercury in human saliva. *Caries Res* 2001; **35**: 163-166 [PMID: 11385194 DOI: 10.1159/000047450]
- 72 **Lindbohm ML**, Ylöstalo P, Sallmén M, Henriks-Eckerman ML, Nurminen T, Forss H, Taskinen H. Occupational exposure in dentistry and miscarriage. *Occup Environ Med* 2007; **64**: 127-133 [PMID: 17053021 DOI: 10.1136/oem.2005.026039]
- 73 **Luglie PF**, Campus G, Chessa G, Spano G, Capobianco G, Fadda GM, Dessole S. Effect of amalgam fillings on the mercury concentration in human amniotic fluid. *Arch Gynecol Obstet* 2005; **271**: 138-142 [PMID: 14689312 DOI: 10.1007/s00404-003-0578-6]
- 74 **Magos L**, Clarkson TW. Overview of the clinical toxicity of mercury. *Ann Clin Biochem* 2006; **43**: 257-268 [PMID: 16824275 DOI: 10.1258/000456306777695654]
- 75 **Mitchell RJ**, Osborne PB, Haubenreich JE. Dental amalgam restorations: daily mercury dose and biocompatibility. *J Long Term Eff Med Implants* 2005; **15**: 709-721 [PMID: 16393137 DOI: 10.1615/JLongTermEffMedImplants.v15.i6.120]
- 76 **Geier DA**, Kern JK, Geier MR. A prospective study of prenatal mercury exposure from maternal dental amalgams and autism severity. *Acta Neurobiol Exp (Wars)* 2009; **69**: 189-197 [PMID: 19593333]
- 77 **Al-Salehi SK**, Hatton PV, Miller CA, Mcleod C, Joiner A. The effect of carbamide peroxide treatment on metal ion release from dental amalgam. *Dent Mater* 2006; **22**: 948-953 [PMID: 16375959 DOI: 10.1016/j.dental.2005.10.006]
- 78 **Rotstein I**, Dogan H, Avron Y, Shemesh H, Steinberg D. Mercury release from dental amalgam after treatment with 10% carbamide peroxide in vitro. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2000; **89**: 216-219 [PMID: 10673659 DOI: 10.1067/moe.2000.102160]
- 79 **Burk JW**. The impact of mercury on the environment. *J Calif Dent Assoc* 2004; **32**: 885; discussion 885 [PMID: 15651464]
- 80 **Chin G**, Chong J, Kluczevska A, Lau A, Gorjy S, Tennant M. The environmental effects of dental amalgam. *Aust Dent J* 2000; **45**: 246-249 [PMID: 11225525 DOI: 10.1111/j.1834-7819.2000.tb00258.x]
- 81 **Costa RD**, Cossich ES, Tavares CR. Influence of the temperature, volume and type of solution in the mercury vaporization of dental amalgam residue. *Sci Total Environ* 2008; **407**: 1-6 [PMID: 18937962 DOI: 10.1016/j.scitotenv.2008.09.013]
- 82 **Farahat SA**, Rashed LA, Zawilla NH, Farouk SM. Effect of occupational exposure to elemental mercury in the amalgam on thymulin hormone production among dental staff. *Toxicol Ind Health* 2009; **25**: 159-167 [PMID: 19482909 DOI: 10.1177/0748233709105270]
- 83 **Fasunloro A**, Owotade FJ. Occupational hazards among clinical dental staff. *J Contemp Dent Pract* 2004; **5**: 134-152 [PMID: 15150641]
- 84 **Jones L**, Bunnell J, Stillman J. A 30-year follow-up of residual effects on New Zealand School Dental Nurses, from occupational mercury exposure. *Hum Exp Toxicol* 2007; **26**: 367-374 [PMID: 17615119 DOI: 10.1177/0960327107076824]
- 85 **Joshi A**, Douglass CW, Kim HD, Joshipura KJ, Park MC, Rimm EB, Carino MJ, Garcia RI, Morris JS, Willett WC. The relationship between amalgam restorations and mercury levels in male dentists and nondental health professionals. *J Public Health Dent* 2003; **63**: 52-60 [PMID: 12597586 DOI: 10.1111/j.1752-7325.2003.tb03474.x]
- 86 **Paksoy CS**, Görgün S, Nalçacı R, Yagbasan A. Assessment of blood mercury levels in practicing Turkish clinicians, dental students, and dental nurses. *Quintessence Int* 2008; **39**: e173-e178 [PMID: 19081894]
- 87 **Trzcinka-Ochocka M**, Gazewski A, Brodzka R. Exposure to mercury vapors in dental workers in Poland. *Int J Occup Med Environ Health* 2007; **20**: 147-153 [PMID: 17638681 DOI: 10.2478/v10001-007-0017-1]
- 88 **Kao RT**, Dault S, Pichay T. Understanding the mercury reduction issue: the impact of mercury on the environment and human health. *J Calif Dent Assoc* 2004; **32**: 574-579 [PMID: 15468538]
- 89 **Lubick N**. Dental offices contribute to methylmercury burden. *Environ Sci Technol* 2008; **42**: 2712 [PMID: 18497108 DOI: 10.1021/es087083k]
- 90 **Beazoglou T**, Eklund S, Heffley D, Meiers J, Brown LJ, Bailit H. Economic impact of regulating the use of amalgam restorations. *Public Health Rep* 2007; **122**: 657-663 [PMID: 17877313]
- 91 **Hickel R**. Trends in materials science from the point of view of a practicing dentist. *J Eur Ceram Soc* 2009; **29**: 1283-1289 [DOI: 10.1016/j.jeurceramsoc.2008.08.014]
- 92 **BUNOCORE MG**. A simple method of increasing the adhesion of acrylic filling materials to enamel surfaces. *J Dent Res* 1955; **34**: 849-853 [PMID: 13271655 DOI: 10.1177/00220345550340060801]
- 93 **Buonocore MG**. Retrospections on bonding. *Dent Clin North Am* 1981; **25**: 241-255 [PMID: 7018935]
- 94 **Suh BI**. All-Bond--fourth generation dentin bonding system. *J Esthet Dent* 1991; **3**: 139-147 [PMID: 1817583 DOI: 10.1111/j.1708-8240.1991.tb00986.x]
- 95 **Bernardo M**, Luis H, Martin MD, Leroux BG, Rue T, Leitão J, DeRouen TA. Survival and reasons for failure of amalgam versus composite posterior restorations placed in a randomized clinical trial. *J Am Dent Assoc* 2007; **138**: 775-783 [PMID: 17545266]
- 96 **Kugel G**, Ferrari M. The science of bonding: from first to sixth generation. *J Am Dent Assoc* 2000; **131** Suppl: 20S-25S [PMID: 10860341]
- 97 **Gwinnett AJ**. Acid etching for composite resins. *Dent Clin North Am* 1981; **25**: 271-289 [PMID: 7018937]
- 98 **Cox CF**, Suzuki S. Re-evaluating pulp protection: calcium hydroxide liners vs. cohesive hybridization. *J Am Dent Assoc* 1994; **125**: 823-831 [PMID: 8040533]
- 99 **Perdigão J**, Lopes M. Dentin bonding--state of the art 1999. *Compend Contin Educ Dent* 1999; **20**: 1151-1158, 1160-1162; quiz 1164 [PMID: 10850267]
- 100 **Nakabayashi N**, Pashley DH. Hybrid layer formation. In: Nakabayashi N, Pashley DH, editors. Hybridization of hard dental tissues. Tokyo: Quintessence, 1998: 8-9
- 101 **Kanca J**. Improving bond strength through acid etching of dentin and bonding to wet dentin surfaces. *J Am Dent Assoc* 1992; **123**: 35-43 [PMID: 1517516]
- 102 **Perdigão J**, Lopes M. Dentin bonding--questions for the new millennium. *J Adhes Dent* 1999; **1**: 191-209 [PMID: 11725668]
- 103 **Kallenos TN**, Al-Badawi E, White GE. An in vitro evaluation of microleakage in class I preparations using 5th, 6th and 7th generation composite bonding agents. *J Clin Pediatr Dent* 2005; **29**: 323-328 [PMID: 16161398]
- 104 **Watts A**, Paterson RC. Cellular responses in the dental pulp: a review. *Int Endod J* 1981; **14**: 10-19 [PMID: 7024136 DOI: 10.1111/j.1365-2591.1981.tb01054.x]
- 105 **Brännström M**, Vojinovic O, Nordenvall KJ. Bacteria and pulp reactions under silicate cement restorations. *J Prosthet Dent* 1979; **41**: 290-295 [PMID: 283229 DOI: 10.1016/0022-3913(79)90009-X]
- 106 **Wright KJ**, Barbosa SV, Araki K, Spångberg LS. In vitro anti-

- microbial and cytotoxic effects of Kri 1 paste and zinc oxide-eugenol used in primary tooth pulpectomies. *Pediatr Dent* 1994; **16**: 102-106 [PMID: 8015949]
- 107 **Food and Drug Administration, HHS.** Dental devices: classification of dental amalgam, reclassification of dental mercury, designation of special controls for dental amalgam, mercury, and amalgam alloy. Final rule. *Fed Regist* 2009; **74**: 38685-38714 [PMID: 19655469]
- 108 **Suh BI,** Cincione FA. All-bond 2: The fourth generation bonding system. *Esthet Dent Update* 1992; **3**: 61-66
- 109 **Kenshima S,** Francci C, Reis A, Loguercio AD, Filho LE. Conditioning effect on dentin, resin tags and hybrid layer of different acidity self-etch adhesives applied to thick and thin smear layer. *J Dent* 2006; **34**: 775-783 [PMID: 16621219 DOI: 10.1016/j.jdent.2006.03.001]
- 110 **Kwong SM,** Cheung GS, Kei LH, Itthagarun A, Smales RJ, Tay FR, Pashley DH. Micro-tensile bond strengths to sclerotic dentin using a self-etching and a total-etching technique. *Dent Mater* 2002; **18**: 359-369 [PMID: 12175574 DOI: 10.1016/S0109-5641(01)00051-3]
- 111 **White KC,** Cox CF, Kanka J, Dixon DL, Farmer JB, Snuggs HM. Pulpal response to adhesive resin systems applied to acid-etched vital dentin: damp versus dry primer application. *Quintessence Int* 1994; **25**: 259-268 [PMID: 8058899]
- 112 **Ferracane JL.** Current trends in dental composites. *Crit Rev Oral Biol Med* 1995; **6**: 302-318 [PMID: 8664421 DOI: 10.1177/10454411950060040301]
- 113 **Suh BI.** A 4th generation universal bonding system. *Asian J Aesthet Dent* 1994; **2**: 19-25 [PMID: 9063110]
- 114 **Griggs JA,** Shen C, Anusavice KJ. Sensitivity of catalyst/base ratio on curing of resin luting agents: polymerization exotherm analysis. *Dent Mater* 1994; **10**: 314-318 [PMID: 7498592 DOI: 10.1016/0109-5641(94)90039-6]
- 115 **Geurtsen W,** Lehmann F, Spahl W, Leyhausen G. Cytotoxicity of 35 dental resin composite monomers/additives in permanent 3T3 and three human primary fibroblast cultures. *J Biomed Mater Res* 1998; **41**: 474-480 [PMID: 9659618]
- 116 **Pameijer CH,** Stanley HR. The disastrous effects of the "total etch" technique in vital pulp capping in primates. *Am J Dent* 1998; **11 Spec No**: S45-S54 [PMID: 9760880]
- 117 **Kitasako Y,** Shibata S, Tagami J. Migration and particle clearance from hard-setting Ca(OH)<sub>2</sub> and self-etching adhesive resin following direct pulp capping. *Am J Dent* 2006; **19**: 370-375 [PMID: 17212080]
- 118 **Bogen G,** Kim JS, Bakland LK. Direct pulp capping with mineral trioxide aggregate: an observational study. *J Am Dent Assoc* 2008; **139**: 305-315; quiz 305-315 [PMID: 18310735]
- 119 **Murray PE,** Lumley PJ, Smith AJ. Preserving the vital pulp in operative dentistry: 3. Thickness of remaining cavity dentine as a key mediator of pulpal injury and repair responses. *Dent Update* 2002; **29**: 172-178 [PMID: 12050883]
- 120 **Carmichael AJ,** Gibson JJ, Walls AW. Allergic contact dermatitis to bisphenol-A-glycidyl dimethacrylate (BIS-GMA) dental resin associated with sensitivity to epoxy resin. *Br Dent J* 1997; **183**: 297-298 [PMID: 9375444 DOI: 10.1038/sj.bdj.4809499]
- 121 **Hensten-Pettersen A.** Skin and mucosal reactions associated with dental materials. *Eur J Oral Sci* 1998; **106**: 707-712 [PMID: 9584904]
- 122 **Munksgaard EC,** Hansen EK, Engen T, Holm U. Self-reported occupational dermatological reactions among Danish dentists. *Eur J Oral Sci* 1996; **104**: 396-402 [PMID: 8930589 DOI: 10.1111/j.1600-0722.1996.tb00098.x]
- 123 **Ortengren U,** Andreasson H, Karlsson S, Meding B, Barregård L. Prevalence of self-reported hand eczema and skin symptoms associated with dental materials among Swedish dentists. *Eur J Oral Sci* 1999; **107**: 496-505 [PMID: 10625110 DOI: 10.1046/j.0909-8836.1999.eos107612.x]
- 124 **Goldberg M.** In vitro and in vivo studies on the toxicity of dental resin components: a review. *Clin Oral Investig* 2008; **12**: 1-8 [PMID: 18040729 DOI: 10.1007/s00784-007-0162-8]
- 125 **Geurtsen- W,** Leyhausen G. Chemical-Biological Interactions of the resin monomer triethyleneglycol-dimethacrylate (TEGDMA). *J Dent Res* 2001; **80**: 2046-2050 [PMID: 11808759 DOI: 10.1177/00220345010800120401]
- 126 **Peumans M,** Van Meerbeek B, Lambrechts P, Vanherle G, Quirynen M. The influence of direct composite additions for the correction of tooth form and/or position on periodontal health. A retrospective study. *J Periodontol* 1998; **69**: 422-427 [PMID: 9609371 DOI: 10.1902/jop.1998.69.4.422]
- 127 **Franz A,** König F, Lucas T, Watts DC, Schedle A. Cytotoxic effects of dental bonding substances as a function of degree of conversion. *Dent Mater* 2009; **25**: 232-239 [PMID: 18774602 DOI: 10.1016/j.dental.2008.07.003]
- 128 **Tabatabaee MH,** Mahdavi H, Zandi S, Kharrazi MJ. HPLC analysis of eluted monomers from two composite resins cured with LED and halogen curing lights. *J Biomed Mater Res B Appl Biomater* 2009; **88**: 191-196 [PMID: 18618467 DOI: 10.1002/jbm.b.31167]
- 129 **Darmani H,** Al-Hiyasat AS, Milhem MM. Cytotoxicity of dental composites and their leached components. *Quintessence Int* 2007; **38**: 789-795 [PMID: 17873986]
- 130 **Müller H,** Olsson S, Söderholm KJ. The effect of comonomer composition, silane heating, and filler type on aqueous TEGDMA leachability in model resin composites. *Eur J Oral Sci* 1997; **105**: 362-368 [PMID: 9298369 DOI: 10.1111/j.1600-0722.1997.tb00253.x]
- 131 **Al-Hiyasat AS,** Darmani H, Milhem MM. Cytotoxicity evaluation of dental resin composites and their flowable derivatives. *Clin Oral Investig* 2005; **9**: 21-25 [PMID: 15635474 DOI: 10.1007/s00784-004-0293-0]
- 132 **Reichl FX,** Simon S, Esters M, Seiss M, Kehe K, Kleinsasser N, Hickel R. Cytotoxicity of dental composite (co)monomers and the amalgam component Hg(2+) in human gingival fibroblasts. *Arch Toxicol* 2006; **80**: 465-472 [PMID: 16474958 DOI: 10.1007/s00204-006-0073-5]
- 133 **Reichl FX,** Walther UI, Durner J, Kehe K, Hickel R, Kunzelmann KH, Spahl W, Hume WR, Benschop H, Forth W. Cytotoxicity of dental composite components and mercury compounds in lung cells. *Dent Mater* 2001; **17**: 95-101 [PMID: 11163377 DOI: 10.1016/S0109-5641(00)00029-4]
- 134 **Schmalz G.** The biocompatibility of non-amalgam dental filling materials. *Eur J Oral Sci* 1998; **106**: 696-706 [PMID: 9584903 DOI: 10.1046/j.0909-8836.1998.eos10602ii05.x]
- 135 **Schweikh H,** Hiller KA, Bolay C, Kreissl M, Kreismann W, Nusser A, Steinhauser S, Wieczorek J, Vasold R, Schmalz G. Cytotoxic and mutagenic effects of dental composite materials. *Biomaterials* 2005; **26**: 1713-1719 [PMID: 15576145 DOI: 10.1016/j.biomaterials.2004.05.025]
- 136 **Schweikh H,** Spagnuolo G, Schmalz G. Genetic and cellular toxicology of dental resin monomers. *J Dent Res* 2006; **85**: 870-877 [PMID: 16998124 DOI: 10.1177/154405910608501001]
- 137 **Cao LY,** Sood A, Taylor JS. Hand/face/neck localized pattern: sticky problems--resins. *Dermatol Clin* 2009; **27**: 227-249, v [PMID: 19580919 DOI: 10.1016/j.det.2009.05.012]
- 138 **Schedle A,** Ortengren U, Eidler N, Gabauer M, Hensten A. Do adverse effects of dental materials exist? What are the consequences, and how can they be diagnosed and treated? *Clin Oral Implants Res* 2007; **18 Suppl 3**: 232-256 [PMID: 17594385 DOI: 10.1111/j.1600-0501.2007.01481.x]
- 139 **Tang AT,** Björkman L, Ekstrand J. New filling materials--an occupational health hazard. *Ann R Australas Coll Dent Surg* 2000; **15**: 102-105 [PMID: 11709913]
- 140 **Knezevic A,** Zeljezic D, Kopjar N, Tarle Z. Influence of curing mode intensities on cell culture cytotoxicity/genotoxicity. *Am J Dent* 2009; **22**: 43-48 [PMID: 19281112]
- 141 **Tillberg A,** Järholm B, Berglund A. Risks with dental materials. *Dent Mater* 2008; **24**: 940-943 [PMID: 18164381 DOI: 10.1016/j.dental.2007.11.009]
- 142 **Statement on posterior resin-based composites.** ADA Coun-

- oil on Scientific Affairs; ADA Council on Dental Benefit Programs. *J Am Dent Assoc* 1998; **129**: 1627-1628 [PMID: 9818585]
- 143 **Murdoch-Kinch CA**, McLean ME. Minimally invasive dentistry. *J Am Dent Assoc* 2003; **134**: 87-95 [PMID: 12555961]
- 144 **Schmalz G**, Arenholt-Bindslev D. Biocompatibility of dental materials. Heidelberg: Springer, 2009
- 145 **Schmalz G**, Geurtsen W. Unwanted biological side effects. In: Kappert HF, Eichner K, editors. Dental Biomaterials and their application. II: Clinical Aspects. Stuttgart: Thieme, 2008: 2-31
- 146 **Krämer N**, García-Godoy F, Frankenberger R. Evaluation of resin composite materials. Part II: in vivo investigations. *Am J Dent* 2005; **18**: 75-81 [PMID: 15973822]
- 147 **Mjör IA**. Biological side effects to materials used in dentistry. *J R Coll Surg Edinb* 1999; **44**: 146-149 [PMID: 10372481]
- 148 **Geukens S**, Goossens A. Occupational contact allergy to (meth)acrylates. *Contact Dermatitis* 2001; **44**: 153-159 [PMID: 11217987 DOI: 10.1034/j.1600-0536.2001.044003153.x]
- 149 **Afsahi SP**, Sydiskis RJ, Davidson WM. Protection by latex or vinyl gloves against cytotoxicity of direct bonding adhesives. *Am J Orthod Dentofacial Orthop* 1988; **93**: 47-50 [PMID: 2962487 DOI: 10.1016/0889-5406(88)90192-8]
- 150 **Aalto-Korte K**, Alanko K, Kuuliala O, Jolanki R. Methacrylate and acrylate allergy in dental personnel. *Contact Dermatitis* 2007; **57**: 324-330 [PMID: 17937748 DOI: 10.1111/j.1600-0536.2007.01237.x]
- 151 **Kieć-Swierczyńska M**, Krecisz B. Allergic contact dermatitis in a dental nurse induced by methacrylates. *Int J Occup Med Environ Health* 2003; **16**: 73-74 [PMID: 12705721]
- 152 **Marcusson JA**. Contact allergies to nickel sulfate, gold sodium thiosulfate and palladium chloride in patients claiming side-effects from dental alloy components. *Contact Dermatitis* 1996; **34**: 320-323 [PMID: 8807223 DOI: 10.1111/j.1600-0536.1996.tb02215.x]
- 153 **Al-Hiyasat AS**, Darmani H, Elbetieha AM. Leached components from dental composites and their effects on fertility of female mice. *Eur J Oral Sci* 2004; **112**: 267-272 [PMID: 15154926 DOI: 10.1111/j.1600-0722.2004.00136.x]
- 154 **Geurtsen W**. Biocompatibility of resin-modified filling materials. *Crit Rev Oral Biol Med* 2000; **11**: 333-355 [PMID: 11021634 DOI: 10.1177/10454411000110030401]
- 155 Posterior composite resins. Council on Dental Materials, Instruments, and Equipment. *J Am Dent Assoc* 1986; **112**: 707-709 [PMID: 3458787]
- 156 **Bacsik CJ**, Swift JQ, Hargreaves KM. Toxic systemic reactions of bupivacaine and etidocaine. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1995; **79**: 18-23 [PMID: 7614153 DOI: 10.1016/S1079-2104(05)80067-8]
- 157 **Cole SR**, Hernán MA. Adjusted survival curves with inverse probability weights. *Comput Methods Programs Biomed* 2004; **75**: 45-49 [PMID: 15158046 DOI: 10.1016/j.cmpb.2003.10.004]
- 158 **Hickel R**, Manhart J. Longevity of restorations in posterior teeth and reasons for failure. *J Adhes Dent* 2001; **3**: 45-64 [PMID: 11317384]
- 159 **Ryge G**, Snyder M. Evaluating the clinical quality of restorations. *J Am Dent Assoc* 1973; **87**: 369-377 [PMID: 4515696]
- 160 **Hujoel PP**. Design and analysis issues in split mouth clinical trials. *Community Dent Oral Epidemiol* 1998; **26**: 85-86 [PMID: 9645400 DOI: 10.1111/j.1600-0528.1998.tb01932.x]
- 161 **Krämer N**, Frankenberger R, Pelka M, Petschelt A. IPS Empress inlays and onlays after four years—a clinical study. *J Dent* 1999; **27**: 325-331 [PMID: 10377606 DOI: 10.1016/S0300-5712(98)00059-1]
- 162 **Eichmiller FC**, Marjenhoff WA. Posterior restorative materials research. *J Calif Dent Assoc* 1996; **24**: 73-76 [PMID: 9120616]

P-Reviewer Eugenia KK S- Editor Huang XZ  
L- Editor A E- Editor Zheng XM



## Effects of low intensity laser irradiation phototherapy on dental pulp constructs

Amr M Elnaghy, Peter E Murray, Paul Bradley, Melissa Marchesan, Kenneth N Namerow, Amany E Badr, Youssry M El-Hawary, Farid A Badria

Amr M Elnaghy, Conservative Dentistry and Endodontics Department, Faculty of Dentistry, Mansoura University, Mansoura 35516, Egypt

Peter E Murray, Melissa Marchesan, Kenneth N Namerow, Department of Endodontics, College of Dental Medicine, Nova Southeastern University, Fort Lauderdale, FL 33328-2018, United States

Paul Bradley, Department of Orofacial Pain, College of Dental Medicine, Nova Southeastern University, Fort Lauderdale, FL 33328-2018, United States

Amany E Badr, Youssry M El-Hawary, Department of Oral Biology, Faculty of Dentistry, Mansoura University, Mansoura 35516, Egypt

Farid A Badria, Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt

Author contributions: All authors contributed equally to this work.

Correspondence to: Dr. Peter E Murray, PhD, Professor, Department of Endodontics, College of Dental Medicine, Nova Southeastern University, 3200 South University Drive, Fort Lauderdale, FL 33328-2018, United States. [petemurr@nova.edu](mailto:petemurr@nova.edu)  
Telephone: +1-954-2621743 Fax: +1-954-2621743

Received: August 25, 2012 Revised: January 4, 2013

Accepted: January 17, 2013

Published online: February 20, 2013

### Abstract

**AIM:** To investigate low intensity laser irradiation phototherapy (LILIP) on the proliferation, mineralization and degradation of dental pulp constructs.

**METHODS:** Stem cells from human exfoliated deciduous teeth (SHED) were grown to confluence and seeded on collagen scaffolds to create dental pulp constructs. LILIP was delivered to the dental pulp constructs using an 830 nm GaAlAs laser at an output power of 20 mW. The LILIP energy density was 0.4, 0.8, 1.2, and 2.4 J/cm<sup>2</sup>. After 8 d, the cell proliferation and degradation within the dental pulp constructs were measured using histologic criteria. After 28 d, the effect

of LILIP on SHED mineralization was assessed by von Kossa staining.

**RESULTS:** SHED proliferation within the dental pulp constructs varied after exposure to the 0.4, 0.8, 1.2, and 2.4 J/cm<sup>2</sup> LILIP energy densities ( $P < 0.05$ ). The maximum proliferation of SHED in nutrient deficient media was 218% after exposure to a 1.2 J/cm<sup>2</sup> LILIP energy density. SHED grown in nutrient deficient media after exposure to a 0.4, 0.8, and 1.2 J/cm<sup>2</sup> LILIP energy density, proliferated by 167-218% compared to the untreated (non-LILIP) control group ( $P < 0.05$ ). SHED exposed to a 0.4, 0.8, and 1.2 J/cm<sup>2</sup> LILIP energy density, and grown in optimal nutritional conditions and proliferated by 147%-164% compared to the untreated (non-LILIP) control group ( $P < 0.05$ ). The exposure of SHED to the highest LILIP energy density (2.4 J/cm<sup>2</sup>) caused a reduction of the cell proliferation of up to 73% of the untreated (non-LILIP) control ( $P < 0.05$ ). The amount of mineral produced by SHED increased over time up to 28 d ( $P < 0.05$ ). The 0.8 and 1.2 J/cm<sup>2</sup> LILIP energy densities were the most effective at stimulating the increased the mineralization of the SHED from 150%-700% compared to untreated (non-LILIP) control over 28 d ( $P < 0.05$ ). The degradation of dental pulp constructs was affected by LILIP ( $P < 0.05$ ). The dental pulp constructs grown in optimal nutritional conditions exposed to a 0.8 J/cm<sup>2</sup> or 1.2 J/cm<sup>2</sup> LILIP energy density had 13% to 16% more degradation than the untreated (non-LILIP) control groups ( $P < 0.05$ ). The other LILIP energy densities caused a 1% degradation of dental pulp constructs in optimal nutritional conditions ( $P > 0.05$ ).

**CONCLUSION:** LILIP can enhance or reduce SHED proliferation, degradation and mineralization within dental pulp constructs. LILIP could promote the healing and regeneration of dental tissues.

© 2013 Baishideng. All rights reserved.

**Key words:** Dental pulp cells; Proliferation; Low intensity laser; Low intensity laser irradiation phototherapy; Stem cells from human exfoliated deciduous teeth

Elnaghy AM, Murray PE, Bradley P, Marchesan M, Namerow KN, Badr AE, El-Hawary YM, Badria FA. Effects of low intensity laser irradiation phototherapy on dental pulp constructs. *World J Stomatol* 2013; 2(1): 12-17 Available from: URL: <http://www.wjgnet.com/2218-6263/full/v2/i1/12.htm> DOI: <http://dx.doi.org/10.5321/wjs.v2.i1.12>

## INTRODUCTION

Regenerative endodontics procedures are biologically based procedures that are used to replace the damaged dentin and root structures of teeth as well as cells of the pulp-dentin complex<sup>[1]</sup>. Regenerative endodontic procedures are: root canal revascularization, apexogenesis, apexification, partial pulpotomy, direct pulp capping, stem cell therapy and dental pulp constructs<sup>[1]</sup>. Endodontic regenerative procedures are widely expected to become more common in coming decades<sup>[2]</sup>. The increased usage of regenerative therapies is likely because of the discovery of dental stem cells, the use of improved treatment protocols, and the availability of new technologies<sup>[1]</sup>. The success of regenerative endodontic procedures is dependent on stimulating the proliferation and mineralization activity of stem cells from human exfoliated deciduous teeth (SHED) and other dental stem cells<sup>[3]</sup>. Previous research has demonstrated pulp healing and regeneration by adding growth factors to increase dental pulp stem cells (DPSCs) activity<sup>[4]</sup>. No previous research has investigated the possibility of using lasers to increase SHED proliferation, mineralization or degradation of scaffolds.

Lasers are beneficial for some dental treatments, such as oral surgery<sup>[5]</sup>, endodontics<sup>[6]</sup>, periodontology<sup>[7]</sup>, and restorative dentistry<sup>[8]</sup>. Low intensity laser irradiation phototherapy (LILIP) can change cell activity<sup>[9]</sup>. LILIP has been used in the treatment of dentin hypersensitivity, gingivitis, periodontitis, and to heal oral ulcers<sup>[10,11]</sup>. In response to LILIP, fibroblast cells can increase their rate of proliferation by 300% to 600%<sup>[12]</sup>. In response to LILIP, epithelial cells cultured in a nutritionally deficient state can dramatically increase their rate of proliferation<sup>[13]</sup>. LILIP can be effective in stimulating the proliferation and mineralization activity of osteoblasts and fibroblasts<sup>[12-14]</sup>. LILIP can increase the proliferation of DPSCs, as indicated by measuring their cell mitochondrial activity using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay<sup>[15]</sup>. Regenerative endodontic procedures require SHED proliferation, mineralization and degradation of scaffolds if they are delivered into teeth as a dental construct<sup>[16,17]</sup> to attempt to regenerate teeth. However, the SHED responses to LILIP have not been evaluated. Consequently, there is a need to investigate the effects of LILIP on SHED proliferation, mineralization, and scaffold degradation, to identify its optimal and in-

jurious effects, prior to its potential use as part of future regenerative endodontic procedures. The aim of this research was to investigate the effects of LILIP on the proliferation and mineralization SHED, and the degradation of dental pulp constructs.

## MATERIALS AND METHODS

### Cell cultures

The SHED was donated under a material transfer agreement with the National Institutes of Dental and Craniofacial Research (Bethesda, MD). Rat fibroblast L929 cells (ATTC, Manassas, VA) were used as a control treatment group cell line. The SHED were cultured in Dulbecco's modified Eagles medium (DMEM; BD Biosciences, Franklin Lakes, NJ) supplemented with 10% or 2.5% fetal bovine serum (FBS) (HyClone, Logan, UT) and 1% gentamycin and amphotericin antibiotic supplement. Cell cultures were maintained at 37 °C in a humidified atmosphere of 5% CO<sub>2</sub> with the culture media being replenished every second day. Confluent cultures of SHED were collected by trypsinization (0.25% trypsin/EDTA; Mediatech, Inc., Herndon, VA).

### Preparation of three-dimensional scaffolds for cell culture

Three-dimensional collagen scaffolds (Collacote; Zimmer Dental, Carlsbad, CA) were cut into 2 mm × 2 mm sheets. Each scaffold was soaked in Hanks' balanced salt solution (HBSS; Cellgro, Herndon, VA) and stored at 4 °C. Before use, the HBSS was replaced by culture medium. The scaffolds were incubated in DMEM at 37 °C for 30 min before application of the cells to equalize culture conditions and temperature between the scaffolds and cells.

### Creation of dental pulp constructs

The SHED were added to the scaffolds in fresh aliquots; each scaffold was seeded with a million ( $\times 10^6$ ) cells to create dental pulp constructs<sup>[16,17]</sup>. The L929 ( $\times 10^6$ ) cells were also applied to the scaffolds as a control treatment. The scaffolds were maintained in 6-well culture plates (BD Biosciences, Franklin Lakes, NY) containing 5 mL of culture media. The DMEM culture media was removed and replenished every 2 d. After 8 d of cell culture, the dental pulp constructs were transferred to 96-well plates.

### Laser irradiation of dental pulp constructs

Laser irradiation was delivered with Gallium-Aluminum-Arsenide (GaAlAs) laser (Asah Medico Uni-Laser, Hvidovre, Denmark). The irradiations were performed in contact with the plate base using the punctual irradiation mode in a 0.252 cm<sup>2</sup> area<sup>[15]</sup>. The 830 nm laser was applied with output power setting of 20 mW. The laser device was calibrated using laser power meter (Model OPM-572; Sanwa, Tokyo, Japan). The clear base of a well from 96-well plate was separated and the laser power output was measured after the laser passed through the base to determine the exact energy density on the cells. This measurement was repeated three times and the aver-

age was calculated. The energy density was applied using 6, 12, 18, and 36 s of irradiation time. The energy density was calculated using the following formula: energy density ( $\text{J}/\text{cm}^2$ ) = [power (W)  $\times$  time (s)]/area ( $\text{cm}^2$ ).

### **Vital staining of SHED in dental pulp constructs**

During the cell culture of the dental pulp constructs, 0.0016% neutral red dye (JT Baker, Phillipsburg, NJ) cell viability marker was added to the DMEM in order to stain the vital cells dark red<sup>[1]</sup>. The SHED and L929s were cultured for 8 d on the collagen scaffolds, with 10 culture replicates for each of the constructs treatments. For each cell type, the experimental groups were: lased 6 s with  $0.4 \text{ J}/\text{cm}^2$ , lased 12 s with  $0.8 \text{ J}/\text{cm}^2$ , lased 18 s with  $1.2 \text{ J}/\text{cm}^2$ , and lased 36 s with  $2.4 \text{ J}/\text{cm}^2$ . The control for this investigation was including constructs without irradiation.

### **Histology of dental pulp constructs**

The dental pulp constructs were removed from cell culture and fixed by submerging them in a 10% neutral-buffered formalin (BDH Chemicals, Poole, United Kingdom) solution for 24 h. All the tissue constructs were then dehydrated in a graded series of alcohols from 70% to 100%. The constructs were then embedded in paraffin wax blocks and cut into serial histologic sections of  $5\text{-}\mu\text{m}$  thickness using a microtome. The histology sections were then mounted onto glass slides and covered with a cover slip using adhesive.

### **Pathohistometric analysis of tissue constructs**

The numbers of stained neutral red SHED were counted as the number of vital metabolically active cells within each of the dental pulp constructs<sup>[16]</sup>. The cells were counted using pathohistometric analysis, the numbers of cells per microscope field with 5 random microscope fields being counted per specimen using a light microscope (Vista vision, VWR Scientific, West Chester, PA) at  $\times 200$  magnifications with a reticule<sup>[18]</sup>. Construct degradation was measured as an area of scaffold that no longer existed using a light microscope at  $\times 200$  magnifications with a reticule.

### **Assessment of mineralization capacity of SHED**

SHED and L929s were cultured and treated with LILIP using the same energy density and 6, 12, 18, and 36 s of irradiation time which was described previously. The SHED and L929s cells were incubated with DMEM mineralization induction media, supplemented with 10 mmol/L sodium  $\beta$ -glycerophosphate (Sigma, St. Louis, MO, United States), for 28 d. The mineralization was assessed by a von Kossa staining (Diagnostic BioSystems, Pleasanton, CA)<sup>[19]</sup>. The mineralized cultures were fixed with 10% buffered formalin for 30 min. Subsequently, they were washed and stained with von Kossa silver and exposed to ultraviolet light for 30 min. Then cells were treated with 5% sodium thiosulfate for 2 min and washed again. The mineralization capacity of each cell line was determined

and compared by measuring the density of mineral nodules formed in each cell type using the tagged image format (tif) image for manipulation in Adobe Photoshop (Adobe Systems, San Jose, CA). Mineralization was measured in three random areas of each specimen.

### **Statistical analysis**

The data were analyzed using an analysis of variance statistical test, followed by Scheffe's multiple comparison tests between treatment groups (Statview, SAS Institute Inc., Cary, NC). A  $P$  value of  $P < 0.05$  was considered statistically significant.

## **RESULTS**

### **LILIP output power and energy density**


The output power setting of 20 mW of the GaAlAs laser was measured by the laser energy meter as 16.83 mW reaching the SHED through the plastic base of the 6 well plates. After applying the LILIP energy density for 6, 12, 18, and 36 s, the energy density was calculated using a formula to be 0.4, 0.8, 1.2, and  $2.4 \text{ J}/\text{cm}^2$ .

### **Nutritionally deficient FBS concentration for SHED**

Prior to experimentation a pilot study of the effects FBS concentrations (10%-1%) within the DMEM culture media found that a 2.5% FBS concentration, was the minimal concentration of FBS necessary to avoid SHED death and reduced cell proliferation. The 2.5% FBS concentration met the criteria<sup>[12,13,15]</sup> to be the conditions of SHED nutritional deficit, and the 10% FBS concentration was the optimal nutritional condition.

### **SHED proliferation following LILIP**

A pilot study revealed that the maximum SHED responses were seen 8 d or more following exposure to LILIP, consequently the SHED responses in this present study were measured 8 d after exposure to LILIP. SHED proliferation within the dental pulp constructs varied after exposure to the 0.4, 0.8, 1.2, and  $2.4 \text{ J}/\text{cm}^2$  LILIP energy densities ( $P < 0.05$ ). The maximum proliferation of SHED in nutrient deficient FBS media was 218% after exposure to a  $1.2 \text{ J}/\text{cm}^2$  LILIP energy density. SHED grown in nutritional deficient media after exposure to a 0.4, 0.8, and  $1.2 \text{ J}/\text{cm}^2$  LILIP energy density, proliferated by 167%-218% compared to the untreated (non-LILIP) control group ( $P < 0.05$ ). SHED exposed to a 0.4, 0.8, and  $1.2 \text{ J}/\text{cm}^2$  LILIP energy density, and grown in optimal nutritional conditions and proliferated by 147%-164% compared to the untreated (non-LILIP) control group ( $P < 0.05$ ). The exposure of SHED to the highest LILIP energy density ( $2.4 \text{ J}/\text{cm}^2$ ) caused a reduction of the cell proliferation of up to 73% of the untreated (non-LILIP) control ( $P < 0.05$ ). The nutrient deficient (2.5%) FBS culture media and optimal (10%) FBS culture media had little effect on the loss of SHED proliferation following exposure to the highest ( $2.4 \text{ J}/\text{cm}^2$ ) LILIP energy density ( $P > 0.05$ ). The loss of proliferation (62%)



**Figure 1** Bar chart of the stem cells from human exfoliated deciduous teeth proliferation within the dental pulp constructs with different low intensity laser irradiation phototherapy energy densities and different fetal bovine serum concentrations. LILIP: Low intensity laser irradiation phototherapy; FBS: Fetal bovine serum.

of L929 was less than the loss of proliferation (73%) of SHED after exposure to the highest (2.4 J/cm<sup>2</sup>) LILIP energy density (Figure 1).

### SHED mineralization following LILIP

The amount of mineral produced by SHED varied 28 d after exposure to 0.4, 0.8, 1.2, and 2.4 J/cm<sup>2</sup> LILIP energy densities ( $P < 0.05$ ). SHED produced (106%-255%) more mineral than L929 cells ( $P < 0.05$ ). The amount of mineral produced by SHED increased over time up to 28 d ( $P < 0.05$ ). The 0.8 and 1.2 J/cm<sup>2</sup> LILIP energy densities were the most effective at stimulating the SHED to produce minerals over 28 d ( $P < 0.05$ ) (Figure 2). The 0.8 and 1.2 J/cm<sup>2</sup> LILIP energy densities increased the mineralization of the SHED from 150%-700% compared to untreated (non-LILIP) control SHED.

### SHED degradation of constructs following LILIP

The degradation of dental pulp constructs was affected by LILIP ( $P < 0.05$ ). The dental pulp constructs grown in optimal nutritional conditions exposed to a 0.8 J/cm<sup>2</sup> or 1.2 J/cm<sup>2</sup> LILIP energy density had 13% to 16% more degradation than the untreated (non-LILIP) control groups ( $P < 0.05$ ). The other LILIP energy densities were less effective at causing the degradation of dental pulp constructs (Figure 3).

## DISCUSSION

Regenerative endodontic procedures are successful because SHED and other dental stem cells can regenerate dentin and dental-pulp tissues<sup>[20]</sup>. The stimulation of SHED to increase proliferation, mineralization and scaffold degradation can be important to ensure that endodontic healing is quick and effective. This is the first investigation of using LILIP to control SHED proliferation, mineralization and construct degradation. This is also the first investigation to determine the optimal and injurious ranges of LILIP energy densities to enhance


and inhibit the activity of a dental stem cell line.

The GaAlAs laser was used with an output power setting of 20 mW, but the laser energy meter measured only 16.83 mW reaching the SHED through the plastic base of the 96 well plates. The loss of 15.9% of the laser energy was factored into the energy densities (0.4, 0.8, 1.2, and 2.4 J/cm<sup>2</sup>) of this present study. A limiting factor in some previous laser studies<sup>[15,21-23]</sup> is that the energy densities reaching the cells were not measured by a meter, and so it is not clear what actual energy density was used. In this study, the LILIP parameters (wavelength, power output, irradiated area), were kept constant, except the irradiation times (6, 12, 18, and 36 s, and their corresponding energy densities (0.4, 0.8, 1.2, and 2.4 J/cm<sup>2</sup>). The GaAlAs laser wavelength was 830 nm, which is ideal for LILIP<sup>[22,23]</sup>, but low energy compared to other laser types.


The effect of LILIP has been studied on several cell types<sup>[12-14]</sup>. A previous study found that LILIP can increase the proliferation of DPSCs, by measuring their cell mitochondrial activity using the MTT assay<sup>[15]</sup>. However, it is not clear what the precise change in the rate of DPSCs proliferation was, or if the 20 mW and 6 s of LILIP energy density<sup>[15]</sup> was the most optimal, since no other energy densities were investigated, or if DPSCs and SHED used in this present study, share similar responses to LILIP.

The present study discovered that the LILIP energy density could enhance or reduce SHED proliferation and degradation within dental pulp constructs. SHED proliferation increased following exposure to 0.4, 0.8, and 1.2 J/cm<sup>2</sup> LILIP energy densities following culture in both the optimum and nutrient deficient FBS conditions. After prolonged exposure to 2.4 J/cm<sup>2</sup> LILIP energy density, the proliferation of SHED was inhibited. The results indicate that a 1.2 J/cm<sup>2</sup> LILIP energy density is optimal to enhance SHED proliferation. This is consistent with previous research demonstrating that LILIP can stimulate cell proliferation in a narrow energy range, and with low energy density<sup>[24]</sup>. Excessive LILIP energy densities can inhibit cell proliferation<sup>[12,23]</sup>. The range of energy densities in this current study which could enhance or reduce SHED activity is in accordance with the Arndt-Shultz Law<sup>[25]</sup>. The Arndt-Shultz Law predicts that a small amount of laser or other source of energy will increase physiological activity, and that a larger amount of the energy will kill cells<sup>[12,23]</sup>. In this study, the energy stimulation range was between 0.4-1.2 J/cm<sup>2</sup> and the energy inhibition occurred at a 2.4 J/cm<sup>2</sup> energy density.

SHED are beneficial for regenerative endodontics because they can differentiate into mineralizing cells which can regenerate teeth<sup>[26]</sup>. In the von Kossa staining part of the present study, the SHED treated with mineralization induction media, we observed to deposit substantial amounts of mineral nodules (black color). The formation of mineral nodules suggests that the SHED differentiated into an odontoblast-like type of cell<sup>[27]</sup>. The SHED had a greater capacity for mineralization than the control L929 cultures. All the cell cultures showed ascending



**Figure 2** Bar chart of the mineralization percentages of stem cells from human exfoliated deciduous teeth cultures with different low intensity laser irradiation phototherapy energy densities and different fetal bovine serum concentrations. LILIP: Low intensity laser irradiation phototherapy; FBS: Fetal bovine serum.



**Figure 3** Bar chart of the degradation within the dental pulp constructs with different low intensity laser irradiation phototherapy energy densities and different fetal bovine serum concentrations. LILIP: Low intensity laser irradiation phototherapy; FBS: Fetal bovine serum.

mineralization percentages from 14-28 d regardless the cell line or the FBS concentrations. The cultures supplemented with optimal FBS concentration showed higher percentages of mineralization than the stressed cultures. This indicates that nutrient deficient SHED has a lower capacity for mineralization, suggesting that a nutrient deficit can reduce cell mineralization activity.

The molecular mechanism whereby LILIP can increase cell activity is reported to be its ability to increase the concentration of calcium in the cytoplasm from the mitochondria<sup>[19,28,29]</sup>. Consequently, the calcium transported into the cytoplasm can increase the rate of cell mitosis and improve cell proliferation. Further research is needed to identify how the molecular mechanisms of cells can be targeted to cause them to proliferate, differentiate and mineralize, as an alternative to the traditional use of growth factors for this purpose<sup>[4]</sup>.

In conclusion, a 1.2 J/cm<sup>2</sup> energy density of LILIP enhances SHED proliferation, dental pulp construct degradation, and mineralization. These results are significant because SHED and other dental cell proliferation, dental pulp construct degradation, and mineralization are needed

to make regenerative endodontics quick and effective. Future clinical research is needed to more completely identify the regeneration benefits of using LILIP, such as following the accidental exposure of the dental pulp, Cvek pulpotomy, tooth revascularization and regeneration.

## COMMENTS

### Background

This is the first article to describe using low intensity laser irradiation phototherapy (LILIP) to control stem cells from human exfoliated deciduous teeth (SHED) proliferation, mineralization and construct degradation. This is also the first article to determine the optimal and injurious ranges of LILIP energy densities to enhance and inhibit the activity of a dental stem cell line.

### Research frontiers

A hotspot of dental research is to develop new therapies which can promote dental tissue healing and regeneration. LILIP could be used to activate SHED and potentially other stem cells to regenerate missing dental tissues.

### Innovations and breakthroughs

At the current time, lasers are most often used to cut soft dental tissues. LILIP is a new type of laser therapy. LILIP could be used more frequently in future dental practice to regenerate missing tissues for patients.

### Applications

Future clinical research is needed to more completely identify the applications of using LILIP, such as to promote the healing of the exposed dental pulp and in conjunction with Cvek pulpotomy, tooth revascularization and regeneration procedures.

### Peer review

The reviewers found the article to be innovative and interesting. The article is significant because it is the first article to evaluate the effects of LILIP on SHED within dental pulp constructs.

## REFERENCES

- 1 Murray PE, Garcia-Godoy F, Hargreaves KM. Regenerative endodontics: a review of current status and a call for action. *J Endod* 2007; **33**: 377-390 [PMID: 17368324 DOI: 10.1016/j.joen.2006.09.013]
- 2 Epelman I, Murray PE, Garcia-Godoy F, Kuttler S, Namerow KN. A practitioner survey of opinions toward regenerative endodontics. *J Endod* 2009; **35**: 1204-1210 [PMID: 19720217 DOI: 10.1016/j.joen.2009.04.059]
- 3 Miura M, Gronthos S, Zhao M, Lu B, Fisher LW, Robey PG, Shi S. SHED: stem cells from human exfoliated deciduous teeth. *Proc Natl Acad Sci USA* 2003; **100**: 5807-5812 [PMID:

- 12716973 DOI: 10.1073/pnas.0937635100]
- 4 **Kikuchi N**, Kitamura C, Morotomi T, Inuyama Y, Ishimatsu H, Tabata Y, Nishihara T, Terashita M. Formation of dentin-like particles in dentin defects above exposed pulp by controlled release of fibroblast growth factor 2 from gelatin hydrogels. *J Endod* 2007; **33**: 1198-1202 [PMID: 17889689 DOI: 10.1016/j.joen.2007.07.025]
  - 5 **Kucerová H**, Dostálová T, Himmlova L, Bártová J, Mazánek J. Low-level laser therapy after molar extraction. *J Clin Laser Med Surg* 2000; **18**: 309-315 [PMID: 11572225]
  - 6 **Kimura Y**, Yamazaki R, Goya C, Tomita Y, Yokoyama K, Matsumoto K. A comparative study on the effects of three types of laser irradiation at the apical stop and apical leakage after obturation. *J Clin Laser Med Surg* 1999; **17**: 261-266 [PMID: 11800098]
  - 7 **Yilmaz S**, Kuru B, Kuru L, Noyan U, Argun D, Kadir T. Effect of gallium arsenide diode laser on human periodontal disease: a microbiological and clinical study. *Lasers Surg Med* 2002; **30**: 60-66 [PMID: 11857606 DOI: 10.1002/lsm.10010]
  - 8 **Ceballos L**, Toledano M, Osorio R, García-Godoy F, Flaitz C, Hicks J. ER-YAG laser pretreatment effect on in vitro secondary caries formation around composite restorations. *Am J Dent* 2001; **14**: 46-49 [PMID: 11806480]
  - 9 **Friedmann H**, Lubart R, Laulich I, Rochkind S. A possible explanation of laser-induced stimulation and damage of cell cultures. *J Photochem Photobiol B* 1991; **11**: 87-91 [PMID: 1791497 DOI: 10.1016/1011-1344(91)80271-I]
  - 10 **Mercer C**. Lasers in dentistry: a review. Part 1. *Dent Update* 1996; **23**: 74-80 [PMID: 8948198]
  - 11 **Walsh LJ**. The current status of low level laser therapy in dentistry. Part 2. Hard tissue applications. *Aust Dent J* 1997; **42**: 302-306 [PMID: 9409045 DOI: 10.1111/j.1834-7819.1997.tb00134.x]
  - 12 **Pereira AN**, Eduardo Cde P, Matson E, Marques MM. Effect of low-power laser irradiation on cell growth and procollagen synthesis of cultured fibroblasts. *Lasers Surg Med* 2002; **31**: 263-267 [PMID: 12355572 DOI: 10.1002/lsm.10107]
  - 13 **Eduardo FP**, Mehnert DU, Monezi TA, Zezell DM, Schubert MM, Eduardo CP, Marques MM. Cultured epithelial cells response to phototherapy with low intensity laser. *Lasers Surg Med* 2007; **39**: 365-372 [PMID: 17457843 DOI: 10.1002/lsm.20481]
  - 14 **Karu T**. Laser biostimulation: a photobiological phenomenon. *J Photochem Photobiol B* 1989; **3**: 638-640 [PMID: 2507763 DOI: 10.1016/1011-1344(89)80088-0]
  - 15 **Eduardo Fde P**, Bueno DF, de Freitas PM, Marques MM, Passos-Bueno MR, Eduardo Cde P, Zatz M. Stem cell proliferation under low intensity laser irradiation: a preliminary study. *Lasers Surg Med* 2008; **40**: 433-438 [PMID: 18649378 DOI: 10.1002/lsm.20646]
  - 16 **Gebhardt M**, Murray PE, Namerow KN, Kuttler S, Garcia-Godoy F. Cell survival within pulp and periodontal constructs. *J Endod* 2009; **35**: 63-66 [PMID: 19084127 DOI: 10.1016/j.joen.2008.09.020]
  - 17 **Gotlieb EL**, Murray PE, Namerow KN, Kuttler S, Garcia-Godoy F. An ultrastructural investigation of tissue-engineered pulp constructs implanted within endodontically treated teeth. *J Am Dent Assoc* 2008; **139**: 457-465 [PMID: 18385030]
  - 18 **Murray PE**, Smith AJ, Garcia-Godoy F, Lumley PJ. Comparison of operative procedure variables on pulpal viability in an ex vivo model. *Int Endod J* 2008; **41**: 389-400 [PMID: 18298576 DOI: 10.1111/j.1365-2591.2007.01364.x]
  - 19 **Liu L**, Ling J, Wei X, Wu L, Xiao Y. Stem cell regulatory gene expression in human adult dental pulp and periodontal ligament cells undergoing odontogenic/osteogenic differentiation. *J Endod* 2009; **35**: 1368-1376 [PMID: 19801232 DOI: 10.1016/j.joen.2009.07.005]
  - 20 **Cordeiro MM**, Dong Z, Kaneko T, Zhang Z, Miyazawa M, Shi S, Smith AJ, Nör JE. Dental pulp tissue engineering with stem cells from exfoliated deciduous teeth. *J Endod* 2008; **34**: 962-969 [PMID: 18634928 DOI: 10.1016/j.joen.2008.04.009]
  - 21 **Tuby H**, Maltz L, Oron U. Low-level laser irradiation (LLL) promotes proliferation of mesenchymal and cardiac stem cells in culture. *Lasers Surg Med* 2007; **39**: 373-378 [PMID: 17457844 DOI: 10.1002/lsm.20492]
  - 22 **Renno AC**, McDonnell PA, Parizotto NA, Laakso EL. The effects of laser irradiation on osteoblast and osteosarcoma cell proliferation and differentiation in vitro. *Photomed Laser Surg* 2007; **25**: 275-280 [PMID: 17803384 DOI: 10.1089/pho.2007.2055]
  - 23 **Renno AC**, McDonnell PA, Crovace MC, Zanotto ED, Laakso L. Effect of 830 nm laser phototherapy on osteoblasts grown in vitro on Biosilicate scaffolds. *Photomed Laser Surg* 2010; **28**: 131-133 [PMID: 19814702 DOI: 10.1089/pho.2009.2487]
  - 24 **Loevschall H**, Arenholt-Bindslev D. Effect of low level diode laser irradiation of human oral mucosa fibroblasts in vitro. *Lasers Surg Med* 1994; **14**: 347-354 [PMID: 8078384 DOI: 10.1002/lsm.1900140407]
  - 25 **Tuner J**, Hode L. Laser therapy. Grangesberg: Prima Books, 2002
  - 26 **Dominici M**, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006; **8**: 315-317 [PMID: 16923606 DOI: 10.1080/14653240600855905]
  - 27 **Yu J**, Wang Y, Deng Z, Tang L, Li Y, Shi J, Jin Y. Odontogenic capability: bone marrow stromal stem cells versus dental pulp stem cells. *Biol Cell* 2007; **99**: 465-474 [PMID: 17371295 DOI: 10.1042/BC20070013]
  - 28 **Manteifel V**, Bakeeva L, Karu T. Ultrastructural changes in chondriome of human lymphocytes after irradiation with He-Ne laser: appearance of giant mitochondria. *J Photochem Photobiol B* 1997; **38**: 25-30 [PMID: 9134752 DOI: 10.1016/S1011-1344(96)07426-X]
  - 29 **Marques MM**, Pereira AN, Fujihara NA, Nogueira FN, Eduardo CP. Effect of low-power laser irradiation on protein synthesis and ultrastructure of human gingival fibroblasts. *Lasers Surg Med* 2004; **34**: 260-265 [PMID: 15022254 DOI: 10.1002/lsm.20008]

P-Reviewer Spagnuolo G S- Editor Wen LL  
L- Editor A E- Editor Zheng XM



## Ozone action on *Streptococcus mutans* and *Lactobacillus fermentum*: A pilot study

Joana Marques, Anabela Paula, Teresa Gonçalves, Manuel Ferreira, Eunice Carrilho

Joana Marques, Anabela Paula, Teresa Gonçalves, Manuel Ferreira, Eunice Carrilho, Faculty of Medicine, the University of Coimbra, Area of Dentistry, Av Bissaya Barreto, Blocos de Celas, 3000-075 Coimbra, Portugal

Author contributions: Marques J, Paula A, Gonçalves T, Ferreira M and Carrilho E designed the research; Marques J, Paula A, Gonçalves T and Carrilho E performed the research; Marques J, Gonçalves T, Ferreira M and Carrilho E analyzed the data; Marques J, Ferreira M and Carrilho E wrote the paper.

Supported by GAPI, Cabinet Support for Research Projects of Faculty of Medicine of the University of Coimbra, process No. 19

Correspondence to: Dr. Joana Marques, Faculty of Medicine, the University of Coimbra, Area of Dentistry, Av Bissaya Barreto, Blocos de Celas, 3000-075 Coimbra, Portugal. [joanaritamarkes@live.com.pt](mailto:joanaritamarkes@live.com.pt)

Telephone: +351-927977880 Fax: +351-239402910

Received: September 19, 2012 Revised: December 26, 2012

Accepted: January 11, 2013

Published online: February 20, 2013

### Abstract

**AIM:** To study the effectiveness of ozone in the elimination of cariogenic bacteria, followed with fluoride supplements.

**METHODS:** Sixty extracted teeth free of caries were used, and five groups were constituted. In Group I, the teeth were immersed in artificial saliva. In Group II, the teeth were inoculated with *Streptococcus mutans* (*S. mutans*) and immersed in artificial saliva. In Group III the teeth were inoculated with *Lactobacillus fermentum* (*L. fermentum*) and immersed in artificial saliva. In Group IV the teeth were inoculated with *S. mutans* and *L. fermentum* and immersed in artificial saliva and the teeth in Group V were inoculated with *S. mutans* and *L. fermentum*, and were subjected to the application of ozone and to the action of a fluoride mineralizing gel. DIAGNOdent was used to evaluate the caries of the

teeth 3 wk after inoculation of bacteria and after that the teeth of Group V were subjected to the application of ozone during 60 s, by HealOzone. After the application of ozone, products of the remineralization kit supplied by the manufacturer were applied daily, during 30 d. At the end samples were collected for analysis and evaluation of bacterial activity by polymerase chain reaction.

**RESULTS:** Regarding the value of caries, obtained *via* DIAGNOdent, in the initial measurement the groups are homogeneous ( $P = 0.730$ ). There was an increase in DIAGNOdent values, presenting statistical significant difference regarding the initial measurement in all groups ( $P < 0.001$ ), except in group I - only artificial saliva - which shows that the artificial carie model was effective. Comparing the initial and final measurements for each of the 60 teeth, it can be observed that in 9 teeth (15.0%) there was a decrease in values between the two measurements, one (1.7%) retained the same values in the two measurements and in the remaining 50 cases (83.3%) there was increase in values between the initial and final measurements. It should also be noted that in the teeth inoculated with *S. mutans* + *L. fermentum*, there was an increase of the values in 100% of cases, and in all groups except the group with artificial saliva, there is a more frequent increase in the values. In group V, subject to the application of ozone, bacterial DNA was not detected, in group IV, bacterial DNA was detected.

**CONCLUSION:** Ozone was effective in the elimination of the study bacteria.

© 2013 Baishideng. All rights reserved.

**Key words:** Dental caries; Cariogenic agents; *Lactobacillus fermentum*; *Streptococcus mutans*; Ozone

Marques J, Paula A, Gonçalves T, Ferreira M, Carrilho E. Ozone action on *Streptococcus mutans* and *Lactobacillus fermentum*: A pilot study. *World J Stomatol* 2013; 2(1): 18-23 Available from:

## INTRODUCTION

Currently dental caries can be defined as a multifactorial and infectious disease, characterized by a localized hard tissue demineralization of tooth, resulting from acidic products, through bacterial fermentation of carbohydrates<sup>[1,2]</sup>.

Clarke<sup>[3]</sup> (1924) identified *Streptococcus mutans* (*S. mutans*) in carious lesions and 36 years later Fitzgerald and Keyes found that these bacteria were capable of inducing caries in hamsters. A number of studies in humans have shown that caries are a confirmation of bacterial infection, primarily mediated by *S. mutans*, which is transmitted through the saliva within the family unit. *Lactobacillus fermentum* (*L. fermentum*) is also associated with the caries process, but is not responsible for it, since it does not have the capacity for the adherence like *S. mutans*<sup>[3]</sup>.

Until today no single factor was found as a caries inducer, instead several factors are proposed such as: microorganisms, diet, teeth and saliva, resulting in the metabolic activity of bacteria that will ferment diet carbohydrates to produce lactic acid<sup>[1,2,4]</sup>. Metabolic activity leads to changes of pH on the interface of the tooth surface and bacterial deposits, producing an imbalance between the enamel and the fluid of the plaque, causing the loss of tooth mineral when pH decreases, or the mineral gain when the pH increases<sup>[1]</sup>. The cumulative result of these processes can be demineralization or remineralization, with mineral loss, leading to dissolution of the dental tissues and the formation of caries<sup>[1]</sup>.

In strategies for management of caries, emphasis has been given to preventive treatments and remineralizing procedures in the early detected stages<sup>[1,5]</sup>. In the presence of caries we have various treatment options. The decision in cavitated teeth becomes simpler, since the treatment choice is conventional drilling and filling<sup>[5]</sup>. In the lesions that are not cavitated, the decisions become more complex, two types of approach can be selected: invasive, assuming that the lesion is active and will progress; or a conservative approach, in order to stop the progression of caries. The latter approach is where emphasis has been placed, leading to more research in this area involving fluoride products and the remineralization process<sup>[6]</sup>. These approaches can be divided into selective invasive interventions and non-invasive interventions, in which ozone is included<sup>[7]</sup>. The non-invasive interventions focus on caries prevention and the preservation of demineralized enamel and dentin, but without cavitation. Under these conditions “restitutio ad integrum” is thought to be possible, by removing bacteria and products of their metabolism and allowing the remineralizing process using fluoride<sup>[7]</sup>.

The antimicrobial effects of ozone have been known for many years<sup>[5]</sup>. The direct application of this gas on

coronary or root surfaces seems to have a sterilization effect<sup>[8]</sup>. It is mentioned that it is able to slow, stop, or reverse the carious process<sup>[7]</sup>. It is believed that the ozone is also useful in reducing the microbial flora in cavitated lesions, before proceeding to filling<sup>[7]</sup>. Although ozone is not a radical, it is the third most potent oxidant<sup>[9]</sup>. Due to its oxidative power, it induces the destruction of the cell walls and membranes, and cytoplasm of bacteria, fungi and certain viruses<sup>[10,11]</sup>. The use of ozone in dentistry has been advocated for the sterilization of cavities, root canal, periodontal pocket and herpetic lesions<sup>[9]</sup>. However, its major indication is in the treatment of caries<sup>[4,5]</sup>. The ozone procedure involves the application of ozone gas, the use of remineralizing agents and an oral hygiene kit to give to the patient, in order to promote the process of remineralization.

The present work aims to assess the effectiveness of ozone in the elimination of cariogenic bacteria.

## MATERIALS AND METHODS

### Teeth preparation

Sixty extracted premolars and molars without caries were selected and stored in a saline solution. The extracted teeth were set in acrylic blocks and numbered. Before using the DIAGNOdent<sup>®</sup> pen 2190 (KAVO GmbH, Biberach, Germany) to evaluate the caries, the teeth were cleaned, dried and selected according the value obtained with DIAGNOdent. An occlusal recess of small size (0.08 mm wide, 1 mm deep and 3 mm in length) was carried out, with a 008 cylindrical diamond drill, placed in turbine with cooling air/water.

### Artificial saliva

Artificial saliva solution was used and prepared based on a modification of the basal medium mucin (BMM) medium with modified Shellis artificial saliva, whose composition is described in the Table 1. The bacteria used were *S. mutans* (ATCC reference: 25 175) and *L. fermentum* (ATCC reference: 14 932). These bacteria were grown and maintained according to the instructions in the ATCC (American Type, Culture and Collection). For inoculation of the samples, bacteria were prepared in phosphate buffered solution (PBS) suspensions. This was subsequently diluted to the final value of 10<sup>5</sup> colony forming units for each bacteria of saliva used for this study. Artificial saliva was supplemented with 2% glucose (20 g/L).

### Constitution of groups

Five groups were formed: Group I - 10 teeth, immersed in artificial saliva; Group II - 10 teeth, inoculated with *L. fermentum* with a bacterial load of 10<sup>5</sup> and immersed in artificial saliva; Group III - 10 teeth, inoculated with *S. mutans* with a bacterial load of 10<sup>5</sup> and immersed in artificial saliva; Group IV - 10 teeth, inoculated with *L. fermentum* and *S. mutans* with a total bacterial load of 2 × 10<sup>5</sup> and immersed in artificial saliva; Group V - 20 teeth inoculated with *L. fermentum* and *S. mutans* with a total bacterial load

**Table 1** Composition of artificial saliva, modification of basal medium mucin Medium with modified artificial Shellis saliva

|  | g/L  |
|--|------|
| Yeast extract  | 5    |
| Proteose peptone   | 10   |
| Potassium chloride (KCl; 74.5 g/mol)   | 1.2  |
| Sodium hydrogen carbonate (NaHCO <sub>3</sub> ; 84 g/L)  | 0.6  |
| Potassium thiocyanate (KSCN; 97.18 g/mol)  | 0.23 |
| Sodium Di-hydrogen phosphate (Na <sub>2</sub> HPO <sub>4</sub> 4.12 H <sub>2</sub> O; 358 g/mol) | 0.9  |

of  $2 \times 10^5$ , subject to the application of ozone followed by fluoride remineralizing gel (supplied by the manufacturer of HealOzone, with sodium fluoride 0, 24% w/w) and immersed in artificial saliva.

All teeth during the experimental protocol were kept in an incubator at 37 °C with permanent stirring at 150 r/min. All procedures performed during the experimental protocol were performed in a laminar flow chamber. The teeth were immersed in artificial saliva and inoculated in accordance with the specifications for each experimental group. DIAGNOdent was used to evaluate the teeth 3 wk after inoculation, as well as the pH, using a pH measuring tape (pH 1-10 Universalindikator Merck).

### Ozone application

The application of Ozone was made with HealOzone® in group V (KAVO GmbH, Biberach, Germany) 3 wk after bacterial inoculation. Before ozone application, the teeth were removed from the medium and washed with a sterile saline solution, and ozone was applied for 60 s. For ozone application a silicone dome was used, which was selected according to the size of each tooth, and changed between each tooth. After application of the ozone a reducing solution was applied, supplied by the manufacturer, for 60 s. Then the teeth were immersed in fresh medium again. Glucose at 0.05% was added to the new medium, also composed of artificial saliva. The bottles were flushed with sterile saline solution before the new medium was inserted. 30 d later, the teeth were brushed with a tooth brush and tooth paste provided by the manufacturer of HealOzone. At the end of brushing a fluoride spray was applied, also supplied by the manufacturer, as a remineralization protocol once a day.

### Sample preparation

Seven weeks after inoculation, a collection of Groups IV and V was made, prepared by excavation of cavities, with a dentin sterile excavator. The samples were stored in PBS and 25% glycerol. The extraction of total DNA from bacteria was performed by the method of proteinase K. Extraction was performed using the protocol of bacteria Lysis Buffer from Roche. After the extraction, the DNA was quantified.

### Statistical analysis

Statistical analysis of results shows the mean values and

standard deviation. Comparison between groups was performed using Kruskal-Wallis test with multiple comparisons and adjusted in each group, by the Wilcoxon test. Comparisons between the initial and final measurements in each tooth and their relation with group was performed using a  $\chi^2$  test with simulation by the Monte Carlo method ( $P < 0.001$ ). All data analysis was performed by SPSS, version 19, at a significance level of 5%.

## RESULTS

Regarding the value of caries, obtained with DIAGNOdent, in the initial measurement groups are homogeneous ( $P = 0.730$ ) but the second measuring statistical difference exist between groups, the differences being detected between groups: group I and group V ( $P < 0.001$ ), group I and group IV ( $P = 0.014$ ), group IV and group V ( $P = 0.036$ ).

There was an increase in DIAGNOdent values, presenting statistical significant difference regarding the initial measurement in all groups, except in the group I, only artificial saliva, see Table 2.

Comparing the initial and final measurements for each of the 60 teeth, it can be observed that in 9 teeth (15.0%) there was a decrease in values between the two measurements, one (1.7%) retained the same values in the two measurements and in the remaining 50 cases (83.3%) there was an increase in values between the initial and final measurements. Although changes are associated with the group, a decrease of the values can be expected only in the group which used artificial saliva and an increase in teeth with *S. mutans* or *S. mutans* + *L. fermentum*. The maintenance of values between measurements occurred in the *L. fermentum* group. It should also be noted that in the teeth inoculated with *S. mutans* + *L. fermentum* there was an increase of the values in 100% of cases, and in all groups except the group with artificial saliva there is a more frequent increase in the values (Table 3).

In group V, subject to the application of ozone, bacterial DNA was not detected. In group IV, bacterial DNA was detected, polymerase chain reaction amplification curves, for some teeth of group IV are presented in Figure 1.

## DISCUSSION

At the beginning of the experimental work, all teeth were free from caries. The highest values accepted, quantified by DIAGNOdent® pen 2190, were 12. According to the recommendations of KaVo, this corresponds to the threshold for considering the tooth tissue normal and healthy. The diagnosis of caries lesions is made after visual and tactile examination of tooth surfaces, however it may be necessary the use auxiliary diagnostic tests<sup>[1]</sup>. A tool developed for the diagnosis and quantification of caries is DIAGNOdent, which is based on tissue fluorescence induced by laser light. In interpreting the values obtained, it is necessary to take into consideration that there may be false positives. These can occur in the fol-

**Table 2 Results of DIAGNOdent, expressed as mean  $\pm$  SE, quartiles and range of variation**

| Material   | Med | n         | Mean  | Structural equation modeling | Min | Max | P25   | P50   | P75   | Med1 vs Med2 |
|--|-----|-----------|-------|------------------------------|-----|-----|-------|-------|-------|--------------|
| Artificial Saliva                                    | 1   | 10        | 6.10  | 0.795                        | 2   | 11  | 4.75  | 6.00  | 7.50  | 0.759        |
|  | 2   | 10        | 8.20  | 4.54                         | 0   | 45  | 0.00  | 1.00  | 14.75 |              |
| <i>L. fermentum</i>                                  | 1   | 10        | 5.40  | 0.792                        | 2   | 10  | 3.00  | 5.50  | 7.25  | 0.011        |
|  | 2   | 10        | 19.40 | 6.31                         | 2   | 63  | 7.00  | 9.50  | 27.50 |              |
| <i>S. mutans</i>                                     | 1   | 10        | 5.60  | 0.859                        | 2   | 9   | 2.00  | 6.50  | 8.00  | 0.011        |
|  | 2   | 10        | 30.00 | 10.33                        | 0   | 99  | 9.25  | 15.50 | 47.00 |              |
| <i>S. mutans</i> + <i>L. fermentum</i>               | 1   | 10        | 6.00  | 0.978                        | 2   | 12  | 4.50  | 5.00  | 8.50  | 0.005        |
|  | 2   | 10        | 31.90 | 3.29                         | 16  | 47  | 25.00 | 29.50 | 43.75 |              |
| <i>S. mutans</i> + <i>L. fermentum</i> ozone + remin | 1   | 20        | 5.15  | 0.782                        | 1   | 12  | 2.25  | 4.00  | 8.75  | < 0.001      |
|  | 2   | 20        | 45.95 | 5.90                         | 20  | 99  | 24.50 | 37.00 | 68.50 |              |
| Comparisons between 5 groups                         | 1   | P = 0.730 |       |                              |     |     |       |       |       |              |
|  | 2   | P < 0.001 |       |                              |     |     |       |       |       |              |

*S. mutans*: *Streptococcus mutans*; *L. fermentum*: *Lactobacillus fermentum*.

**Table 3 Measurements difference for each of 60 teeth**

|             |           |         | Group             |                     |                  |  |  | Total |
|-------------|-----------|---------|-------------------|---------------------|------------------|--|--|-------|
|             |           |         | Artificial saliva | <i>L. fermentum</i> | <i>S. mutans</i> | <i>S. mutans</i> + <i>L. fermentum</i> | <i>S. mutans</i> + <i>L. fermentum</i> + ozone |       |
| Difference  | Decreased | n (%)   | 7                 | 1                   | 1                | 0                                      | 0  | 9     |
|             |           | Residue | 5.5               | -0.5                | -0.5             | -1.5                                   | -3.0   |       |
| Maintenance |           | n (%)   | 0                 | 1                   | 0                | 0                                      | 0  | 1     |
|             |           | Residue | -0.2              | 0.8                 | -0.2             | -0.2                                   | -0.3   |       |
| Increased   |           | n (%)   | 3                 | 8                   | 9                | 10                                     | 20   | 50    |
|             |           | Residue | -5.3              | -0.3                | 0.7              | 1.7                                    | 3.3  |       |
| Total       |           |         | 10                | 10                  | 10               | 10                                     | 20   | 60    |

*S. mutans*: *Streptococcus mutans*; *L. fermentum*: *Lactobacillus fermentum*.

lowing situations: teeth with plaque; fillings with fluorescent composites; proximity of the pulp; food waste; prophylactic pastes; remineralized cavities; increased natural fluorescence and patients exposed to radiation.

Three weeks after bacterial inoculation, the presence of caries was evaluated in all groups, using DIAGNOdent<sup>®</sup> pen 2190. Some authors claim that the diagnostic technologies such ECM (Electric Caries Meter) and DIAGNOdent, perform better in the early detection of caries in occlusal surfaces, compared with visual examination<sup>[12]</sup>. Goel *et al.*<sup>[13]</sup> in 2009 conducted an *in vivo* study that compares the efficacy of DIAGNOdent with conventional methods (visual, tactile and bitewings radiographs). The authors concluded that DIAGNOdent showed high precision compared to conventional methods for the detection of enamel caries. However, when the cavities reach dentine, although precision is high, it is similar to other diagnostic methods. The DIAGNOdent is the diagnostic method chosen for this work since it allows the quantification of dental caries, has good accuracy, reproducibility, sensitivity and validity<sup>[12,13]</sup>.

Plaque in humans is a complex biofilm comprising hundreds of microbiological species<sup>[14]</sup>. The culture plaque using the BMM medium, exhibits similar growth rates behaviour to the natural. Oral fluids are the major source of nutrients to bacterial plaque<sup>[14]</sup>. Several stud-

ies simulating these oral fluids *in vitro* contained as main components mucin, yeast extract and/or peptones. One of these formulations is the BMM medium, which has been widely used for *in vitro* studies of oral bacteria<sup>[14]</sup>. The presence of yeast extract and peptones contributes to the presence of a variable concentration of peptides, vitamins and ions in the medium<sup>[14]</sup>. Shellis in 1978 developed an artificial saliva, chemically defined, containing various ions, amino acids, vitamins, growth factors and bovine origin mucin<sup>[14]</sup>. This has as its major components potassium chloride, sodium chloride, sodium hydrogen-carbonate and potassium thiocyanate<sup>[14]</sup>.

The artificial saliva used in this experimental study consisted of a modification of BMM medium, with modified Shellis saliva, which since the system used was a simple one, only comprises two bacteria. To allow a greater bacterial growth prior to inoculation of bacteria on teeth, the artificial saliva was supplemented with 2% glucose, to allowing the formation of lactic acid by fermentation.

After the appearance of the tooth caries and application of ozone, the teeth were immersed in new medium, the same as used earlier, but without glucose supplementation, since the carious lesion was established and the concentration of glucose in yeast extract must correspond to 0.05% and the concentration of glucose in saliva in an adult is 0.01%<sup>[15]</sup>.




Figure 1 Polymerase chain reaction amplification curves of real-time for the group IV, inoculated with *Streptococcus mutans* and *Lactobacillus fermentum*.

In order to promote bacterial retention on site and to allow faster development of the caries process, we performed a cavity of small dimensions on the occlusal surface as the occlusal surfaces are particularly susceptible to caries<sup>[1]</sup>.

The antimicrobial effect of ozone has been shown by several studies<sup>[11,16]</sup>. However there are studies that show conflicting results, such as those done by Baysan *et al*<sup>[17]</sup> in 2007, which demonstrated that the application of ozone in carious lesions of dentin did not significantly reduce the number of bacteria detected in infected dentin in non-cavitated caries. Castillo *et al*<sup>[11]</sup> in 2008 conducted an *in vitro* study, which used 41 strains of *S. mutans* including native strains obtained from the saliva of 27 children, which after being cultured, were placed in eppendorf. The ozone was applied to the eppendorf and the results show that after application of ozone for 40 s, no bacteria were viable. Polydorou *et al*<sup>[6]</sup> in 2006, compared the antibacterial effect of ozone with two dentin adhesive systems. The adhesive systems showed significant antibacterial activity. However, application of ozone has proved a promising in eliminating residual microorganisms in deep cavities and potentially increases the clinical success of fillings. Knight *et al*<sup>[18]</sup> in 2008 conducted an *in vitro* study to determine the effects of ozone application in dentin before the formation of a biofilm. The study showed that the ozone application prevents the formation of a biofilm of *S. mutans* and *Lactobacillus acidophilus* for a

period of 4 wk.

Studies conducted to evaluate the efficacy of ozone in carious lesions in pits and fissures and roots already have a good level of scientific evidence, since they are randomized. However, there are authors who raise questions about the evaluation method, which is in most cases performed by DIAGNOdent, and as to whether the participants were aware of the treatment administered to them (only the study by Holmes is double-blind) and that many of the studies were conducted by the team members from the main precursor of this therapy, Edward Lynch<sup>[10]</sup>. Systematic reviews on the subject are unanimous about the fact that more scientific evidence is needed that this therapy can be accepted as an alternative therapeutic approach to early detected caries<sup>[5,10]</sup>.

From the study it can be concluded that the caries induction protocol employed in this study was effective in the development of caries lesions. The application of ozone through HealOzone for 60 s, at a concentration of 2100 ppm was effective in eliminating caries bacteria. No bacterial DNA was detected after the application of ozone, followed by the daily application of the remineralizing products for 30 d. The treatment with ozone is advantageous in minimally invasive dentistry, it maintains the healthy tissue, and does not require anaesthesia, and with a simple and non-time-consuming process presents satisfactory results. More evidence is still needed before the cost-benefit ratio can be assessed.

## ACKNOWLEDGMENTS

To Paulo Ferreira e Nuno Brito for their help, during the experimental work.

## COMMENTS

### Background

Carious lesions occur due to acid dissolution of the enamel and/or dentin as a result of the metabolism of specific microorganisms, the main ones being *Streptococcus mutans* (*S. mutans*) and *Lactobacillus fermentum* (*L. fermentum*). Ozone is a powerful oxidant that has the ability to eliminate 99% of bacteria, fungi and viruses. Once the bacteria is eliminated, the remineralization may occur in the treated area.

### Research frontiers

The bacterias *S. mutans* and *L. fermentum* are effective in producing tooth decay immersed in artificial saliva, and ozone was able to eliminate them. In this study the authors shows the capability of ozone in their elimination.

### Innovations and breakthroughs

This is the first study to demonstrated the capability of bacteria elimination by the ozone, by polymerase chain reaction. Demonstrating that the ozone is highly effective. This study by demonstrated the bacteria elimination, shows that the ozone provides conditions for the remineralization.

### Applications

Ozone therapy is advantageous in minimally invasive dentistry, because it maintains healthy tissue, does not require anesthesia and with a simple and non-time-consuming procedure gives satisfactory results.

### Terminology

The carie occurs due to acid dissolution of the enamel and/or dentin as a result of the metabolism of specific microorganisms, the main are *S. mutans* and *L. fermentum*. Ozone is oxidant that has the ability to eliminate bacteria, fungi and viruses.

### Peer review

The manuscript is good to add some information on the antibacterial effect of ozone in dental caries.

## REFERENCES

- 1 Fejerskov O, Kidd E. *Cárie Dentária: A Doença e seu Tratamento Clínico*. São Paulo: Livraria Santos Editora, 2005
- 2 Selwitz RH, Ismail AI, Pitts NB. Dental caries. *Lancet* 2007; **369**: 51-59 [PMID: 17208642]
- 3 Anderson MH, Bales DJ, Omnell KA. Modern management of dental caries: the cutting edge is not the dental bur. *J Am Dent Assoc* 1993; **124**: 36-44 [PMID: 8505449]
- 4 Johansson E, Claesson R, van Dijken JW. Antibacterial effect of ozone on cariogenic bacterial species. *J Dent* 2009; **37**: 449-453 [PMID: 19342147 DOI: 10.1016/j.jdent.2009.02.004]
- 5 Lindtjörn B. Disaster epidemiology. *Lancet* 1991; **337**: 116-117 [PMID: 1670703]
- 6 Doméjean-Orliaguet S, Léger S, Auclair C, Gerbaud L, Tubert-Jeannin S. Caries management decision: influence of dentist and patient factors in the provision of dental services. *J Dent* 2009; **37**: 827-834 [PMID: 19628326 DOI: 10.1016/j.jdent.2009.06.012]
- 7 Lynch E. *Ozone: the revolution in dentistry*. London: Quintessence Publishing Co. Ltd., 2004
- 8 Millar BJ, Hodson N. Assessment of the safety of two ozone delivery devices. *J Dent* 2007; **35**: 195-200 [PMID: 17030396 DOI: 10.1016/j.jdent.2006.07.010]
- 9 Nogales CG, Ferrari PH, Kantorovich EO, Lage-Marques JL. Ozone therapy in medicine and dentistry. *J Contemp Dent Pract* 2008; **9**: 75-84 [PMID: 18473030]
- 10 Azarpazhooh A, Limeback H. The application of ozone in dentistry: a systematic review of literature. *J Dent* 2008; **36**: 104-116 [PMID: 18166260 DOI: 10.1016/j.jdent.2007.11.008]
- 11 Castillo A, Galindo-Moreno P, Avila G, Valderrama M, Liébana J, Baca P. In vitro reduction of mutans streptococci by means of ozone gas application. *Quintessence Int* 2008; **39**: 827-831 [PMID: 19093059]
- 12 Pereira AC, Eggertsson H, Martinez-Mier EA, Mialhe FL, Eckert GJ, Zero DT. Validity of caries detection on occlusal surfaces and treatment decisions based on results from multiple caries-detection methods. *Eur J Oral Sci* 2009; **117**: 51-57 [PMID: 19196318 DOI: 10.1111/j.1600-0722.2008.00586.x]
- 13 Goel A, Chawla HS, Gauba K, Goyal A. Comparison of validity of DIAGNOdent with conventional methods for detection of occlusal caries in primary molars using the histological gold standard: an in vivo study. *J Indian Soc Pedod Prev Dent* 2009; **27**: 227-234 [PMID: 19915274 DOI: 10.4103/0970-4388.57658]
- 14 Wong L, Sissons C. A comparison of human dental plaque microcosm biofilms grown in an undefined medium and a chemically defined artificial saliva. *Arch Oral Biol* 2001; **46**: 477-486 [PMID: 11311195]
- 15 Di Gioia ML, Leggio A, Le Pera A, Liguori A, Napoli A, Siciliano C, Sindona G. Quantitative analysis of human salivary glucose by gas chromatography-mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2004; **801**: 355-358 [PMID: 14751806]
- 16 Polydorou O, Pelz K, Hahn P. Antibacterial effect of an ozone device and its comparison with two dentin-bonding systems. *Eur J Oral Sci* 2006; **114**: 349-353 [PMID: 16911107]
- 17 Baysan A, Beighton D. Assessment of the ozone-mediated killing of bacteria in infected dentine associated with non-cavitated occlusal carious lesions. *Caries Res* 2007; **41**: 337-341 [PMID: 17713332 DOI: 10.1159/000104790]
- 18 Knight GM, McIntyre JM, Craig GG, Mulyani PS. The inability of *Streptococcus mutans* and *Lactobacillus acidophilus* to form a biofilm in vitro on dentine pretreated with ozone. *Aust Dent J* 2008; **53**: 349-353 [PMID: 19133951 DOI: 10.1111/j.1834-7819.2008.00077.x]

**P-Reviewers** Messora M, Ardila M, Pekkan G, Zhong LP, Abu El-Naaj I, Aggarwal V **S- Editor** Huang XZ  
**L- Editor** A **E- Editor** Zheng XM



## MMP-8 analysis in gingival crevicular fluid using ELISA and novel chair-side test

Ghousia Akbari, MLV Prabhuji, Bangalore Varadhan Karthikeyan, Sandip G Chorghade

Ghousia Akbari, Department of Periodontics, M.S. Ramaiah Dental College and Hospital, Bengaluru 560054, India

MLV Prabhuji, Bangalore Varadhan Karthikeyan, Department of Periodontics, Krishnadevaraya College of Dental Sciences, Bengaluru 562157, India

Sandip G Chorghade, Department of Microbiology and Cell Biology, Indian Institute of Science, Bengaluru 560054, India

**Author contributions:** All the authors have substantially contributed to the design of the study, acquisition of data and drafting and revising the article.

**Correspondence to:** Ghousia Akbari, MDS, Department of Periodontics, M.S. Ramaiah Dental College and Hospital, MSR Nagar, MSRIT post, Bengaluru 560054, India. [drghousiaakbari@yahoo.com](mailto:drghousiaakbari@yahoo.com)

Telephone: +91-87-92141535 Fax: +91-80-23601825

Received: November 3, 2012 Revised: January 8, 2013

Accepted: January 11, 2013

Published online: February 20, 2013

### Abstract

**AIM:** To validate accuracy of a novel chair-side test for matrix metalloproteinase (MMP)-8 as compared to enzyme-linked immunosorbent assay (ELISA) in Periodontal health and disease.

**METHODS:** Gingival crevicular fluid was collected from 150 subjects, Group 1 (healthy) - 50 subjects, Group 2 (gingivitis) - 50 subjects and Group 3 (chronic periodontitis) - 50 subjects. A chair-side test strip was indigenously prepared using polyclonal antibodies (principle of immunochromatography) to detect the MMP-8 levels. The detection accuracy (sensitivity and specificity) of the MMP-8 levels by chair-side test kit were compared with ELISA at baseline and 3 mo after scaling and root planing among the study population.

**RESULTS:** The novel chair side test detected MMP-8 levels in accordance with ELISA which at baseline were higher in Group 2 and Group 3 as compared to controls ( $P < 0.05$ ), and these enzyme levels decreased

after therapy ( $P < 0.05$ ). The chair-side test could differentiate healthy, gingivitis and periodontitis. The detection accuracy of the chair-side test strip were on par with ELISA (sensitivity 92.9% and specificity of 100%) which were statistically significant ( $P < 0.05$ ). A desire to arouse interest about periodontal health and maintenance in the Indian population provided a strong rationale for us to develop our chair-side test strips to suit our economy. Moreover, this was the first ever effort to develop and validate a chair-side test strip to detect MMP-8 levels in the Indian population. This test can be used on a large scale in private dental practice for the early detection of disease, tapping the sites at risk for disease, alongside helps in patient education and motivation for maintenance.

**CONCLUSION:** This study shows that the novel chair side test kit detects MMP-8 levels a biomarker of periodontal disease progression accurately making it a good chair side diagnostic tool. Further, it is cost effective and time saving which can make it applicable in private dental practice on a large scale for the early detection of periodontal disease.

© 2013 Baishideng. All rights reserved.

**Key words:** Chair-side test; Chronic periodontitis; Gingival crevicular fluid; Matrix metalloproteinase-8; Periodontal health

Akbari G, Prabhuji MLV, Karthikeyan BV, Chorghade SG. MMP-8 analysis in gingival crevicular fluid using ELISA and novel chair-side test. *World J Stomatol* 2013; 2(1): 24-29 Available from: URL: <http://www.wjgnet.com/2218-6263/full/v2/i1/24.htm> DOI: <http://dx.doi.org/10.5321/wjs.v2.i1.24>

### INTRODUCTION

Periodontal diseases are chronic inflammatory diseases of

the supporting structures of the teeth. Though periodontitis is often triggered by periodontopathogens, its clinical outcome is highly influenced by the host local immune response<sup>[1]</sup>. In view of the irreversible nature of progressive periodontitis, an early diagnosis and treatment of this disease is important. An early diagnosis will help prevent further irreversible loss of connective tissue attachment of teeth and adjacent alveolar bone associated with periodontal disease<sup>[2,3]</sup>. It is a well-established fact that the host immune products in periodontitis are synthesized locally and appear within the gingival crevicular fluid (GCF). This makes GCF ideal for obtaining diagnostic information of periodontal health or disease status<sup>[4]</sup>. The markers thus identified include cytokines, prostaglandins, bacterial- as well as host-derived enzymes, and connective tissue-degradation products, alongside bone matrix components that are primarily isolated in the GCF<sup>[5]</sup>.

Matrix metalloproteinases (MMPs) are one such Group of enzymes which play a key role in the mediation of tissue destruction in periodontitis. MMP-8, a collagenase synthesized by neutrophils, is the major metalloproteinase implicated in the degradation and remodeling of the extracellular matrix. MMP-8 has a strong affinity towards type I collagen, which is present in abundance in the periodontal tissues<sup>[6]</sup>. There is growing evidence which indicate that a predominant association exists between increased GCF collagenase activity and disease progression, as it is extensively distributed in diseased periodontal tissues. A significant decrease in the GCF MMP-8 activity has been demonstrated following successful non-surgical periodontal therapy<sup>[7,8]</sup>. The potentiality of MMP-8 as a biomarker of periodontal disease progression is evident from literature.

Keeping this in view, the first chair-side, point-of-care dip-stick test based on the principle of immunochromatography utilizing monoclonal antibodies was developed and tested successfully to detect MMP 8 levels in GCF<sup>[9]</sup>. However, it was not popularized to be used on a large scale in private dental practice, probably because there were no further studies reported in literature evaluating and validating its use on a large sample size; Secondly, cost of the test kit could have escalated with the use of monoclonal antibody.

This fact provides a strong clinical rationale to indigenously develop a point-of-care test utilizing polyclonal antibody which is cost effective compared to monoclonal based test kit for MMP-8 detection with a diagnostic accuracy on par with enzyme-linked immunosorbent assay (ELISA). To overcome this limitation we indigenously developed a novel chair side point of care dip stick test based on the principle of immunochromatography utilizing polyclonal antibody (cost effective) instead of monoclonal antibody to detect MMP-8. The objective of the current study is to validate diagnostic accuracy (sensitivity and specificity) of our indigenously developed a novel chair-side test kit compared to that of ELISA in periodontal health and disease. Further to check the cost-

effectiveness to suit the economies of developing countries like India.

## MATERIALS AND METHODS

### Study population

The study population consisted of 187 subjects (77 males and 90 females), 30-39 years of age, who were screened from the outpatient section of Department of Periodontics, Krishnadevaraya College of Dental Sciences and Hospital, Bangalore and 150 subjects (75 males and 75 females) were recruited for the study that was conducted during April to May 2010.

The following criteria prevented the patients from being included in the study Groups: medically compromised patients requiring prophylactic antibiotics, patients on antibiotic therapy within the last 6 mo, patients who had received any form of periodontal therapy surgical or non-surgical within 6 mo of baseline examination, smokers, pregnant patients, patients with recent orthodontic treatment, pulpal or periapical involvement on the qualifying teeth.

Each subject underwent a full mouth periodontal probing and charting, the subjects were categorized into three Groups based on clinical examination of gingival index (GI) (Loe and Silness, 1963), plaque index (PI) (Turesky Gilmore Glickman modification of the Quigley and Hein plaque index, 1970) and probing pocket depth (PPD) using a UNC15 probe. Fifty subjects with clinically healthy periodontium, mean PI  $\leq 1$ , mean GI  $\leq 1$ , no PPD, were included in Group 1. Group 2 (gingivitis Group) consisted of Fifty subjects with gingival inflammation as indicated by the mean PI  $\geq 2$ , GI  $\geq 2$  and the absence of PPD. Group 3 (chronic periodontitis) consisted of fifty subjects with a mean PI  $\geq 2$ , GI  $\geq 2$  and PPD  $\geq 5$  mm falling in the category of severe periodontitis as per the classification. Therefore of the patients recruited in the study, Group 1 had individuals with a healthy periodontium, Group 2 included individuals with gingivitis and no attachment loss and those in Group 3 were diagnosed to have severe chronic periodontitis. Groups 2 and 3 were treated with non surgical approach, scaling and root planning was done using area-specific Gracey currets (Hu friedy) and ultrasonic scalers.

Subjects satisfying the above criteria for enrolment were selected consecutively, and ethical clearance for the study was obtained from the institutional ethical review board, Rajiv Gandhi University of Health Sciences, in accordance with the guidelines of Indian council of Medical research. Written informed consent as per the declaration of Helsinki 2008 was obtained from those who agreed to participate in the study.

### Site selection and collection of GCF

The study was a triple blind prospective cross-sectional study in which clinical examination, Group allocation and sample site selection was performed by one examiner, the

samples were collected on the subsequent day by the second examiner, and a third examiner carried out the post-treatment clinical examination. This was done to ensure masking of the sampling examiner and to prevent contamination of GCF with blood associated with the probing of inflamed sites. One site per subject was sampled, in gingivitis patients, site with most severe clinical inflammatory signs (in gingivitis cases) or greatest amount of probing depth (in chronic periodontitis cases), along with radiographic confirmation of alveolar bone loss, and the same test site was selected for the after-treatment Group.

On the subsequent day, after drying the area with blast of air, supragingival plaque was removed without touching the marginal gingiva to eliminate the possibility of saliva contamination and thereafter GCF was collected. A standardized volume of 3  $\mu\text{L}$  was collected from each test sites using the calibration of colour coded 1-5  $\mu\text{L}$  calibrated volumetric microcapillary pipettes (Sigma Aldrich, St. Louis, MO) with an extracurricular (unstimulated) method. The test site, which did not express any volume of GCF, and microcapillary pipettes suspected of being contaminated with blood and saliva were excluded from the study. In such cases the sample was obtained from the tooth that showed the next highest PPD in the same patient. The GCF collected was transferred to eppendorf tubes containing 0.5 mL of phosphate buffer saline and stored at  $-70^\circ\text{C}$  until the time of assay.

Though cumbersome this method of GCF collection was adopted as to prevent protein binding to the paper strips and the risk of sample evaporation.

### MMP-8 assay

The samples were assayed for MMP-8 levels using commercially available ELISA kit. The assays were conducted according to the manufacturer's instructions. Highly sensitive ELISA kit (Booster Biological technology Co., LTD, Shanghai) was used to detect the enzyme levels in the sample. This kit reported an assay of sensitivity of  $< 10\text{ pg/mL}$ . In relation to specificity, the manufacturer reported no significant cross reactivity or interference for the ELISA kit. The samples were run in duplicates. The kit made use of biotinylated anti-human MMP-8 antibody and Avidin-Biotin-Peroxidase Complex. Absorbance of the substrate colour reaction was read on ELISA reader using 450 nm wavelengths. The total MMP-8 level was determined in nanograms (ng), and the calculation of the concentration in each sample was performed by dividing the amount of enzyme by the volume of sample (ng/mL).

### Fabrication of point-of-care test sticks for chair-side monitoring

The chair-side test was fabricated based on the sandwich ELISA principle. Nitrocellulose membrane of pore size  $0.45\ \mu\text{m}$  was cut into small strips. One end of the strip was treated with methanol to make the membrane hydrophilic. Methanol was washed off using  $0.01\text{ mol/L}$

phosphate buffered saline (PBS) buffer.  $1\ \mu\text{L}$  of a primary polyclonal antibody to human MMP-8 was added to the hydrophilic end of the nitrocellulose membrane and allowed to dry. GCF sample collected was transferred to an eppendorf tube containing  $0.5\text{ mL}$  of  $0.01\text{ mol/L}$  PBS buffer. The test strip was immersed into this tube to allow the sample to bind the primary antibody. The strip was removed and washed thoroughly in the PBS buffer to remove the unbound sample. The strip was then dipped in an eppendorf tube containing secondary antibody to human MMP-8 conjugated with a peroxidase system for 10-15 min. The strips were washed in the buffer again and transferred to another eppendorf tube to which a colour developing solution was added. The solution turns blue in colour for samples positive for MMP-8. A colour change within 5 min was recorded as +++ (strongly positive), a change between 5 to 10 min was recorded as ++ (moderately positive) and a change in colour after 15 min was recorded as + (weakly positive). The individual reading the test results was unaware of the ELISA results to eliminate bias and ensure blinding.

### Statistical analysis

Analysis of variance was used to compare all variables between groups and a  $P$  value of  $\leq 0.05$  was considered to be statistically significant. SPSS version 13 was used for all the analysis.

## RESULTS

Recruitment of subjects for the study started in the first week of April 2010, recruitment ended by the end of the second week of April. 187 subjects (77 males and 80 females), 30-39 years of age, were screened from the outpatient section of Department of Periodontics, Krishnadevaraya College of Dental Sciences and Hospital, Bangalore. Of the 187 individuals screened only one hundred and fifty subjects (75 males and 75 females) were available for analysis. GCF MMP-8 levels measured by enzyme linked immune sorbent assay were able to distinguish sites with periodontitis from those with gingivitis and healthy sites. All samples in each Group tested positive for MMP-8. The highest mean concentration of MMP-8 was obtained in Group 3 ( $1948.65 \pm 916.44\text{ mg/mL}$ ), and the lowest mean concentration was obtained in Group 1 ( $96.90 \pm 30.88\text{ mg/mL}$ ). The mean MMP-8 concentration for Group 2 ( $797.94 \pm 185.60\text{ mg/mL}$ ) was intermediate between the healthy and periodontitis sites. GCF MMP-8 levels  $> 1\text{ mg/mL}$  especially helped to differentiate the periodontitis from gingivitis and healthy sites, and  $1\text{ mg/mL}$  was used as cut-off point in the chair-side test as previously reported (Tables 1 and 2).

A significant improvement in clinical parameters was observed after treatment (Table 3).  $\kappa$  statistics were performed to know the degree of agreement between the test stick and ELISA results.  $\kappa$  value was 0.959, indicating

**Table 1** Descriptive data showing comparison of enzyme-linked immunosorbent assay and test stick results

| Visit    | Group    | Test stick results | MMP-8 (mg/L) |     | Total |
|----------|----------|--------------------|--------------|-----|-------|
|          |          |                    | > 1          | ≤ 1 |       |
| Baseline | Group 1  | Positive           | 1            | 1   |       |
|          |          | Negative           | 49           | 49  |       |
|          |          | Total              | 50           | 50  |       |
|          | Group 2  | Positive           | 4            | 0   | 4     |
|          |          | Negative           | 8            | 38  | 46    |
|          |          | Total              | 12           | 38  | 50    |
| Group 3  | Positive | 30                 | 2            | 32  |       |
|          | Negative | 5                  | 13           | 18  |       |
|          | Total    | 35                 | 15           | 50  |       |
| 3 mo     | Group 1  | Positive           | 1            | 1   |       |
|          |          | Negative           | 49           | 49  |       |
|          |          | Total              | 50           | 50  |       |
|          | Group 2  | Negative           | 50           | 50  |       |
|          |          | Total              | 50           | 50  |       |
|          |          | Positive           | 13           | 0   | 13    |
|          | Group 3  | Negative           | 0            | 37  | 37    |
|          |          | Total              | 13           | 37  | 50    |

MMP: Matrix metalloproteinase.

**Table 2** Test strip results at baseline and three month follow-up

| Visit    | Group   | Site | Test result of site | MMP-8 (mg/L) |          |
|----------|---------|------|---------------------|--------------|----------|
|          |         |      |                     | ≤ 1 mg/L     | > 1 mg/L |
| Baseline | Group 1 | 50   | Positive            | 1            | 0        |
|          |         |      | Negative            | 49           | 0        |
|          | Group 2 | 50   | Positive            | 0            | 4        |
|          |         |      | Negative            | 38           | 8        |
|          | Group 3 | 50   | Positive            | 2            | 30       |
|          |         |      | Negative            | 13           | 5        |
| 3rd mo   | Group 1 | 50   | Positive            | 0            | 1        |
|          |         |      | Negative            | 0            | 49       |
|          | Group 2 | 50   | Positive            | 0            | 0        |
|          |         |      | Negative            | 0            | 50       |
|          | Group 3 | 50   | Positive            | 0            | 13       |
|          |         |      | Negative            | 37           | 0        |

a good agreement between the two tests at both baseline as well as the third month follow-up.

## DISCUSSION

MMP-8 or collagenase-2 is one of the central biomarkers in the breakdown of periodontal connective tissue during the transition from health to disease<sup>[7,10-13]</sup> besides it has been found to be a potential candidate for use in diagnostic aids<sup>[14,15]</sup>.

A triple blind prospective study was done to gain an insight into the diagnostic accuracy of the MMP-8 chair-side test and check its cost-effectiveness for application on a large scale. A possible role of MMP-8 as a mediator of periodontal inflammation and a comparison of the levels of MMP-8 in GCF among the three study Groups namely Group 1, Group 2, and Group 3 and after treatment in Group 2, and Group 3 was assessed using our chair-side point of care test as well as ELISA. Since there

**Table 3** Changes in clinical parameters from baseline to three months following scaling and root planning *n* (%)

| Visit    | Bleeding on Probing | Probing pocket depth |            | Total      |
|----------|---------------------|----------------------|------------|------------|
|          |                     | ≥ 5 mm               | < 5 mm     |            |
| Baseline | Negative            | 8 (30.8)             | 8 (33.3)   | 16 (32.0)  |
|          | Positive            | 18 (69.2)            | 16 (66.7)  | 34 (68.0)  |
|          | Total               | 26 (100.0)           | 24 (100.0) | 50 (100.0) |
| 3 mo     | Negative            |                      | 43 (86.0)  | 43 (86.0)  |
|          | Positive            |                      | 7 (14.0)   | 7 (14.0)   |
|          | Total               |                      | 50 (100.0) | 50 (100.0) |

have been reports on age-dependent changes in inflammatory mediators, we selected subjects in the age Group of 30-39 years to control the influence of age on the levels of MMP-8<sup>[16]</sup>. Further, a single site was selected for sample collection from each participant, which precluded the pooling of samples from multiple sites. Unstimulated samples were collected as an increase in vascular permeability of the blood vessels following gingival stimulation has been reported<sup>[17]</sup>, suggesting that the levels of MMPs in GCF could be influenced by stimulation in sampling.

To the authors' knowledge, this study was the first of its kind to investigate the GCF levels of MMP-8 in the Indian population. Furthermore, this was the first attempt to tailor a chair-side diagnostic test to detect these enzyme levels in Indian population and suit their economic status as well. Though previous studies have successfully designed a chair-side test it had few shortcomings, firstly, the cost of the test strip which was escalated due to the use of monoclonal antibodies. Second, there was no data on post-treatment assessment of MMP-8 levels using the chair-side test which would have been of great help in patient education and motivation, and to identify the site at risk for disease progression.

The main finding of our study was that a strong association exists between the MMP-8 levels and the degree of inflammation as indicated by the changes in clinical parameters and the enzyme levels. The chair-side test strips also showed good agreement in this accord as depicted by the  $\kappa$  values. The specificity and sensitivity of the test strip were found to be good (sensitivity 92.9% and specificity of 100%).

Test strips were fabricated using polyclonal antibodies instead of the monoclonal antibodies previously used, this cut down the cost of the chair-side test almost three-fold. Moreover, the specificity and sensitivity remained on par with the previously designed test, this further confirmed that the specificity and sensitivity obtained with either polyclonal or monoclonal antibodies remained almost the same<sup>[18]</sup> validating our results.

Even though ELISA is a highly sensitive assay and is widely used to detect various biomarkers to aid in diagnosis of various diseases there were certain limitations of ELISA, like technique sensitivity, the time consuming, a delay in providing results to the patients and the cost

involved favoured the fabrication of an easy to use chair-side test strip.

Our chair-side test strip confirmed that it serves as a good diagnostic tool and helps in early detection and maintenance of patients. However, due to the cross-sectional setting of the present study no definite conclusion can be drawn in this regard. To overcome this limitation of the present study, more number of multicenter trials need to be carried out with larger sample sizes. In the near future the chair-side tests could help in the diagnosis of at risk sites in periodontal patients as well as in the early detection and control of periodontal disease in patients at risk due to various systemic and environmental factors. Currently, a randomized controlled trial on a large sample size is being carried out by our organization to tap the at risk population with our new chair-side diagnostic test strip for MMP-8 detection. Apart from this another trial using the chair-side MMP-8 test is being used to detect MMP-8 levels in saliva samples as well to make it less cumbersome and more cost effective.

In short, it can be said that MMP-8 levels reflects the levels of inflammation in the tissues and this can be maintained at low levels with good patient education and regular maintenance. Currently, ELISA is widely used to detect biomarkers of various diseases. But it has some limitation like technique sensitivity and time consuming and cannot be adopted as a chair-side diagnostic aid. The quest to develop a rapid chair-side diagnostic aid with high validity prompted us to fabricate an indigenous chair-side point of care test.

## COMMENTS

### Background

Periodontitis is a complex, multifactorial disease, whose progression depends on the interplay between periodontopathogens, environmental factors and the host response. Matrix metalloproteinase-8 (MMP-8) is one of the major enzymes of host response to influence the degradation of the periodontal connective tissues. Many studies have proved this role of MMP-8, a chair-side test kit was also fabricated but was not popularized.

### Research frontiers

The detection of MMP-8 by various methods has been carried out regularly. However, a point-of-care chair-side test with diagnostic accuracy on par with the regular methods like enzyme-linked immunosorbent assay as well as economic stability was lacking in developing countries like India. In this study, the authors demonstrated the accuracy of an indigenously prepared chair-side test which was suitable for large scale private practice use as well.

### Innovations and breakthroughs

This study confirmed that a strong association exists between the MMP-8 levels and the degree of inflammation as indicated by the changes in clinical parameters and the enzyme levels. The chair-side test strips also showed good agreement in this accord as depicted by the  $\kappa$  values. The specificity and sensitivity of the test strip were found to be good (sensitivity 92.9% and specificity of 100%). Therefore it serves as a good diagnostic tool and helps in early detection and maintenance of patients.

### Applications

Thus the indigenously fabricated test can be used along chair-side to detect the MMP-8 levels and identify at risk sites and patients thus aiding in an early diagnosis and good maintenance of periodontal patients.

### Terminology

MMPs are matrix metalloproteinases, which represent a Group of Zinc dependent enzymes involved in connective tissue degradation. Of these MMP-8 is the major enzyme with an affinity towards collagens.

dent enzymes involved in connective tissue degradation. Of these MMP-8 is the major enzyme with an affinity towards collagens.

### Peer review

This study is interesting and the results are useful to the readers. The authors concluded that the novel chair side test kit detects MMP-8 levels a biomarker of periodontal disease progression accurately making it a cost effective and time saving diagnostic tool. It really adds new information. It is a prospective well designed research study with interesting results. The paper is well written with appropriate structure. Thus, it could be accepted for publication.

## REFERENCES

- 1 **Kinane DF**, Lappin DF. Clinical, pathological and immunological aspects of periodontal disease. *Acta Odontol Scand* 2001; **59**: 154-160 [PMID: 11501884 DOI: 10.1080/000163501750266747]
- 2 **Kinane DF**. Regulators of tissue destruction and homeostasis as diagnostic aids in periodontology. *Periodontol* 2000 2000; **24**: 215-225 [PMID: 11276868 DOI: 10.1034/j.1600-0757.2000.2240110.x]
- 3 **McCulloch CA**. Host enzymes in gingival crevicular fluid as diagnostic indicators of periodontitis. *J Clin Periodontol* 1994; **21**: 497-506 [PMID: 7929863]
- 4 **Ebersole JL**. Humoral immune responses in gingival crevice fluid: local and systemic implications. *Periodontol* 2000 2003; **31**: 135-166 [PMID: 12657000 DOI: 10.1034/j.1600-0757.2003.03109.x]
- 5 **Eley BM**, Cox SW. Advances in periodontal diagnosis. 4. Potential microbiological markers. *Br Dent J* 1998; **184**: 161-166 [PMID: 9549909 DOI: 10.1038/sj.bdj.4809568]
- 6 **Balbin M**, Fueyo A, Knäuper V, Pendás AM, López JM, Jiménez MG, Murphy G, López-Otín C. Collagenase 2 (MMP-8) expression in murine tissue-remodeling processes. Analysis of its potential role in postpartum involution of the uterus. *J Biol Chem* 1998; **273**: 23959-23968 [PMID: 9727011 DOI: 10.1074/jbc.273.37.23959]
- 7 **Lee W**, Aitken S, Sodek J, McCulloch CA. Evidence of a direct relationship between neutrophil collagenase activity and periodontal tissue destruction in vivo: role of active enzyme in human periodontitis. *J Periodontol Res* 1995; **30**: 23-33 [PMID: 7722844 DOI: 10.1111/j.1600-0765.1995.tb01249.x]
- 8 **Chen HY**, Cox SW, Eley BM, Mäntylä P, Rönkä H, Sorsa T. Matrix metalloproteinase-8 levels and elastase activities in gingival crevicular fluid from chronic adult periodontitis patients. *J Clin Periodontol* 2000; **27**: 366-369 [PMID: 10847542 DOI: 10.1034/j.1600-051x.2000.027005366.x]
- 9 **Sorsa T**, Mäntylä P, Rönkä H, Kallio P, Kallis GB, Lundqvist C, Kinane DF, Salo T, Golub LM, Teronen O, Tikanoja S. Scientific basis of a matrix metalloproteinase-8 specific chair-side test for monitoring periodontal and peri-implant health and disease. *Ann N Y Acad Sci* 1999; **878**: 130-140 [PMID: 10415725 DOI: 10.1111/j.1749-6632.1999.tb07679.x]
- 10 **Mancini S**, Romanelli R, Laschinger CA, Overall CM, Sodek J, McCulloch CA. Assessment of a novel screening test for neutrophil collagenase activity in the diagnosis of periodontal diseases. *J Periodontol* 1999; **70**: 1292-1302 [PMID: 10588492 DOI: 10.1902/jop.1999.70.11.1292]
- 11 **Sorsa T**, Uitto VJ, Suomalainen K, Vauhkonen M, Lindy S. Comparison of interstitial collagenases from human gingiva, sulcular fluid and polymorphonuclear leukocytes. *J Periodontol Res* 1988; **23**: 386-393 [PMID: 2851042 DOI: 10.1111/j.1600-0765.1988.tb01618.x]
- 12 **Sorsa T**, Tjäderhane L, Salo T. Matrix metalloproteinases (MMPs) in oral diseases. *Oral Dis* 2004; **10**: 311-318 [PMID: 15533204 DOI: 10.1111/j.1601-0825.2004.01038.x]
- 13 **Sorsa T**, Tjäderhane L, Konttinen YT, Lauhio A, Salo T, Lee HM, Golub LM, Brown DL, Mäntylä P. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. *Ann Med* 2006; **38**:

- 306-321 [PMID: 16938801 DOI: 10.1080/07853890600800103]
- 14 **Mäntylä P**, Stenman M, Kinane DF, Tikanoja S, Luoto H, Salo T, Sorsa T. Gingival crevicular fluid collagenase-2 (MMP-8) test stick for chair-side monitoring of periodontitis. *J Periodontol Res* 2003; **38**: 436-439 [PMID: 12828663 DOI: 10.1034/j.1600-0765.2003.00677.x]
- 15 **Mäntylä P**, Stenman M, Kinane D, Salo T, Suomalainen K, Tikanoja S, Sorsa T. Monitoring periodontal disease status in smokers and nonsmokers using a gingival crevicular fluid matrix metalloproteinase-8-specific chair-side test. *J Periodontol Res* 2006; **41**: 503-512 [PMID: 17076774 DOI: 10.1111/j.1600-0765.2006.00897]
- 16 **Chakraborti T**, Mandal M, Das S, Chakraborti S. Age-dependent change in arachidonic acid metabolic capacity in rat alveolar macrophages. *Biochem Mol Biol Int* 1999; **47**: 501-507 [PMID: 10204087 DOI: 10.1080/15216549900201533]
- 17 **Sueda T**, Bang J, Cimasoni G. Collection of gingival fluid for quantitative analysis. *J Dent Res* 1969; **48**: 159 [PMID: 5252093 DOI: 10.1177/00220345690480011501]
- 18 **Lauhio A**, Salo T, Ding Y, Konttinen YT, Nordström D, Tschesche H, Lähdevirta J, Golub LM, Sorsa T. In vivo inhibition of human neutrophil collagenase (MMP-8) activity during long-term combination therapy of doxycycline and non-steroidal anti-inflammatory drugs (NSAID) in acute reactive arthritis. *Clin Exp Immunol* 1994; **98**: 21-28 [PMID: 7923879 DOI: 10.1111/j.1365-2249.1994.tb06601.x]

**P-Reviewers** Pavlidis TE, Chen MK **S-Editor** Huang XZ  
**L-Editor** A **E-Editor** Zheng XM



**GENERAL INFORMATION**

*World Journal of Stomatology* (*World J Stomatol*, *WJS*, online ISSN 2218-6263, DOI: 10.5321) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

**Aim and scope**

*WJS* covers topics concerning oral and craniofacial sciences, oral and craniofacial development/growth, dental tissue regeneration, craniofacial bone and cartilage research, oral and maxillofacial genetic diseases, developmental abnormalities and soft tissue defects, pulpal and periapical diseases, periodontal diseases and oral mucosal diseases, salivary gland diseases, oral and maxillofacial vascular/nervous diseases, jaw bone diseases, taste abnormalities, oral and maxillofacial pain, occlusion and temporomandibular diseases, repair and treatment of tooth defects, loss and dento-maxillofacial deformities, oral and maxillofacial biomechanics and biomaterials, new techniques for diagnosis/treatment of oral and maxillofacial diseases; and stomatology-related evidence-based medicine, epidemiology and nursing. The current columns of *WJS* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography. Priority publication will be given to articles concerning diagnosis and treatment of stomatologic diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJS*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

*WJS* is edited and published by Baishideng Publishing Group (BPG). BPG has a strong professional editorial team composed of science editors, language editors and electronic editors. BPG currently publishes 42 OA clinical medical journals, including 41 in English, has a total of 15 471 editorial board members or peer reviewers, and is a world first-class publisher.

**Columns**

The columns in the issues of *WJS* will include: (1) Editorial: The editorial board members are invited to make comments on an important topic in their field in terms of its current research status and future directions to lead the development of this discipline; (2) Frontier: The editorial board members are invited to select a highly cited cutting-edge original paper of his/her own to summarize major findings, the problems that have been resolved and remain to be resolved, and future research directions to help readers understand his/her important academic point of view and future research directions in the field; (3) Diagnostic Advances: The editorial board members are invited to write high-quality diagnostic advances in their field to improve the diagnostic skills of readers. The topic covers general clinical diagnosis, differential diagnosis, pathological diagnosis, laboratory diagnosis, imaging diagnosis, endoscopic diagnosis, biotechnological diagnosis, functional diagnosis, and physical diagnosis; (4) Therapeutics Advances: The editorial board members

are invited to write high-quality therapeutic advances in their field to help improve the therapeutic skills of readers. The topic covers medication therapy, psychotherapy, physical therapy, replacement therapy, interventional therapy, minimally invasive therapy, endoscopic therapy, transplantation therapy, and surgical therapy; (5) Field of Vision: The editorial board members are invited to write commentaries on classic articles, hot topic articles, or latest articles to keep readers at the forefront of research and increase their levels of clinical research. Classic articles refer to papers that are included in Web of Knowledge and have received a large number of citations (ranking in the top 1%) after being published for more than years, reflecting the quality and impact of papers. Hot topic articles refer to papers that are included in Web of Knowledge and have received a large number of citations after being published for no more than 2 years, reflecting cutting-edge trends in scientific research. Latest articles refer to the latest published high-quality papers that are included in PubMed, reflecting the latest research trends. These commentary articles should focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions. Basic information about the article to be commented (including authors, article title, journal name, year, volume, and inclusive page numbers); (6) Minireviews: The editorial board members are invited to write short reviews on recent advances and trends in research of molecular biology, genomics, and related cutting-edge technologies to provide readers with the latest knowledge and help improve their diagnostic and therapeutic skills; (7) Review: To make a systematic review to focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions; (8) Topic Highlight: The editorial board members are invited to write a series of articles (7-10 articles) to comment and discuss a hot topic to help improve the diagnostic and therapeutic skills of readers; (9) Medical Ethics: The editorial board members are invited to write articles about medical ethics to increase readers' knowledge of medical ethics. The topic covers international ethics guidelines, animal studies, clinical trials, organ transplantation, etc.; (10) Clinical Case Conference or Clinicopathological Conference: The editorial board members are invited to contribute high-quality clinical case conference; (11) Original Articles: To report innovative and original findings in stomatology; (12) Brief Articles: To briefly report the novel and innovative findings in stomatology; (13) Meta-Analysis: To evaluate the clinical effectiveness in stomatology by using data from two or more randomised control trials; (14) Case Report: To report a rare or typical case; (15) Letters to the Editor: To discuss and make reply to the contributions published in *WJS*, or to introduce and comment on a controversial issue of general interest; (16) Book Reviews: To introduce and comment on quality monographs of stomatology; and (17) Autobiography: The editorial board members are invited to write their autobiography to provide readers with stories of success or failure in their scientific research career. The topic covers their basic personal information and information about when they started doing research work, where and how they did research work, what they have achieved, and their lessons from success or failure.

**Name of journal**

*World Journal of Stomatology*

**ISSN**

ISSN 2218-6263 (online)

## Instructions to authors

### Launch date

November 31, 2011

### Frequency

Quarterly

### Editor-in-Chief

**Peter E Murray, BSc (Hons), PhD, Professor, Pathologist,**  
Department of Endodontics, College of Dental Medicine, Nova  
Southeastern University, 3200 South University Drive, Fort Lauderdale,  
FL 33328-2018, United States

### Editorial office

Jin-Lei Wang, Director  
Xiu-Xia Song, Vice Director  
*World Journal of Stomatology*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381891  
Fax: +86-10-85381893  
E-mail: wjs@wjgnet.com  
<http://www.wjgnet.com>

### Publisher

Baishideng Publishing Group Co., Limited  
Flat C, 23/F, Lucky Plaza, 315-321 Lockhart Road,  
Wan Chai, Hong Kong, China  
Telephone: +852-58042046  
Fax: +852-31158812  
E-mail: bpgoffice@wjgnet.com  
<http://www.wjgnet.com>

### Production center

Beijing Baishideng BioMed Scientific Co., Limited  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381892  
Fax: +86-10-85381893

### Representative office

USA Office  
8226 Regency Drive,  
Pleasanton, CA 94588-3144, United States

### Instructions to authors

Full instructions are available online at [http://www.wjgnet.com/2218-6263/g\\_info\\_20100722180909.htm](http://www.wjgnet.com/2218-6263/g_info_20100722180909.htm).

### Indexed and Abstracted in

Digital Object Identifier.

---

## SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

### Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Redit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, etc. The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their

95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

### Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJS* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: [http://www.icmje.org/ethical\\_4conflicts.html](http://www.icmje.org/ethical_4conflicts.html).

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

### Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

### Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

---

## SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory ani-

mals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

### Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/esps/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS ([http://www.wjgnet.com/2218-6263/g\\_info\\_20100722180909.htm](http://www.wjgnet.com/2218-6263/g_info_20100722180909.htm)) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to [wjs@wjgnet.com](mailto:wjs@wjgnet.com), or by telephone: +86-10-85381892. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

## MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

### Title page

**Title:** Title should be less than 12 words.

**Running title:** A short running title of less than 6 words should be provided.

**Authorship:** Authorship credit should be in accordance with the standard proposed by ICMJE, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

**Institution:** Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

**Author contributions:** The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

**Supportive foundations:** The complete name and number of sup-

portive foundations should be provided, e.g., Supported by National Natural Science Foundation of China, No. 30224801

**Correspondence to:** Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. [montgomerybissell@ucsf.edu](mailto:montgomerybissell@ucsf.edu)

**Telephone and fax:** Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g., Telephone: +86-10-85381892 Fax: +86-10-85381893

**Peer reviewers:** All articles received are subject to peer review. Normally, three experts are invited for each article. Decision on acceptance is made only when at least two experts recommend publication of an article. All peer-reviewers are acknowledged on Express Submission and Peer-review System website.

### Abstract

There are unstructured abstracts (no less than 200 words) and structured abstracts. The specific requirements for structured abstracts are as follows:

An informative, structured abstract should accompany each manuscript. Abstracts of original contributions should be structured into the following sections: AIM (no more than 20 words; Only the purpose of the study should be included. Please write the Aim in the form of "To investigate/study/..."), METHODS (no less than 140 words for Original Articles; and no less than 80 words for Brief Articles), RESULTS (no less than 150 words for Original Articles and no less than 120 words for Brief Articles; You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g.,  $6.92 \pm 3.86$  vs  $3.61 \pm 1.67$ ,  $P < 0.001$ ), and CONCLUSION (no more than 26 words).

### Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

### Core tip

Please write a summary of less than 100 words to outline the most innovative and important arguments and core contents in your paper to attract readers.

### Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both.

### Illustrations

Figures should be numbered as 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the E-versions.

## Instructions to authors

### Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

### Notes in tables and illustrations

Data that are not statistically significant should not be noted. <sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, <sup>c</sup>*P* < 0.05 and <sup>d</sup>*P* < 0.01 are used. A third series of *P* values can be expressed as <sup>e</sup>*P* < 0.05 and <sup>f</sup>*P* < 0.01. Other notes in tables or under illustrations should be expressed as <sup>1</sup>F, <sup>2</sup>F, <sup>3</sup>F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a certain sequence.

### Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

## REFERENCES

### Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability<sup>[1,2]</sup>". If references are cited directly in the text, they should be put together within the text, for example, "From references<sup>[19,22-24]</sup>, we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

### PMID and DOI

Please provide PubMed citation numbers to the reference list, *e.g.*, PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

### Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

### Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

### Format

#### Journals

*English journal article (list all authors and include the PMID where applicable)*

1 Jung EM, Clevert DA, Schreyer AG, Schmitt S, Rennert J,

Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

*Chinese journal article (list all authors and include the PMID where applicable)*

2 Lin GZ, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

*In press*

3 Tian D, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

*Organization as author*

4 Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMCID:2516377 DOI:10.1161/01.HYP.00000035706.28494.09]

*Both personal authors and an organization as author*

5 Vallancien G, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

*No author given*

6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

*Volume with supplement*

7 Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

*Issue with no volume*

8 Banit DM, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

*No volume or issue*

9 Outreach: Bringing HIV-positive individuals into care. *HRS: A Careaction* 2002; 1-6 [PMID: 12154804]

### Books

*Personal author(s)*

10 Sherlock S, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

*Chapter in a book (list all authors)*

11 Lam SK. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

*Author(s) and editor(s)*

12 Breedlove GK, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

*Conference proceedings*

13 Harnden P, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

*Conference paper*

14 Christensen S, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

*Electronic journal (list all authors)*

15 Morse SS. Factors in the emergence of infectious diseases.

Emerg Infect Dis serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

#### Patent (list all authors)

16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

#### Statistical data

Write as mean  $\pm$  SD or mean  $\pm$  SE.

#### Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as  $\chi^2$  (in Greek), related coefficient as *r* (in italics), degree of freedom as  $\nu$  (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

#### Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h; blood glucose concentration, *c* (glucose)  $6.4 \pm 2.1$  mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 24.5  $\mu$ g/L; CO<sub>2</sub> volume fraction, 50 mL/L CO<sub>2</sub>, not 5% CO<sub>2</sub>; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23243641.

The format for how to accurately write common units and quantum numbers can be found at: [http://www.wjgnet.com/2218-6263/g\\_info\\_20100725073806.htm](http://www.wjgnet.com/2218-6263/g_info_20100725073806.htm).

#### Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

#### Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

#### Examples for paper writing

All types of articles' writing style and requirement will be found in the link: <http://www.wjgnet.com/esps/NavigationInfo.aspx?id=15>

## RESUBMISSION OF THE REVISED MANUSCRIPTS

Authors must revise their manuscript carefully according to the revision policies of Baishideng Publishing Group Co., Limited. The revised version, along with the signed copyright transfer agreement, responses to the reviewers, and English language Grade A certificate (for non-native speakers of English), should be submitted to the online system *via* the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to [esps@wjgnet.com](mailto:esps@wjgnet.com).

#### Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A.

#### Copyright assignment form

Please download a Copyright assignment form from [http://www.wjgnet.com/2218-6263/g\\_info\\_20100725073726.htm](http://www.wjgnet.com/2218-6263/g_info_20100725073726.htm).

#### Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: [http://www.wjgnet.com/2218-6263/g\\_info\\_20100725073445.htm](http://www.wjgnet.com/2218-6263/g_info_20100725073445.htm).

#### Proof of financial support

For papers supported by a foundation, authors should provide a copy of the approval document and serial number of the foundation.

#### Links to documents related to the manuscript

WJIS will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

#### Publication fee

WJIS is an international, peer-reviewed, OA online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium and format, provided the original work is properly cited. The use is non-commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 600 USD per article. All invited articles are published free of charge.



百世登

**Baishideng**®

Published by **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza, 315-321 Lockhart Road,

Wan Chai, Hong Kong, China

Fax: +852-31158812

Telephone: +852-58042046

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

